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Abstract. Leukaemia inhibitory factor (LIF) and oncostatin M (OSM) are pleiotropic cytokines present at the
implantation site that are important for the normal development of human pregnancy. These cytokines share the cell
membrane receptor subunit gp130, resulting in similar functions. The aim of this study was to compare the response to LIF
and OSM in several trophoblast models with particular regard to intracellular mechanisms and invasion. Four trophoblast
cell lines with different characteristics were used: HTR-8/SVneo, JEG-3, ACH-3P and AC1-M59 cells. Cells were
incubated with LIF, OSM (both at 10 ngmL1) and the signal transducer and activator of transcription (STAT) 3 inhibitor
S3I-201 (200 mM). Expression and phosphorylation of STAT3 (tyr705) and extracellular regulated kinase (ERK) 1/2
(thr202/204) and the STAT3 DNA-binding capacity were analysed by Western blotting and DNA-binding assays,
respectively. Cell viability and invasiveness were assessed by the methylthiazole tetrazolium salt (MTS) and Matrigel
assays. Enzymatic activity of matrix metalloproteinase (MMP)-2 andMMP-9 was investigated by zymography. OSM and
LIF triggered phosphorylation of STAT3 and ERK1/2, followed by a significant increase in STAT3DNA-binding activity
in all tested cell lines. Stimulation with LIF but not OSM significantly enhanced invasion of ACH-3P and JEG-3 cells, but
not HTR-8/SVneo or AC1-M59 cells. Similarly, STAT3 inhibition significantly decreased the invasiveness of only ACH-
3P and JEG-3 cells concomitant with decreases in secreted MMP-2 and MMP-9. OSM shares with LIF the capacity to
activate ERK1/2 and STAT3 pathways in all cell lines tested, but their resulting effects are dependent on cell type. This
suggests that LIF and OSM may partially substitute for each other in case of deficiencies or therapeutic interventions.
Additional keywords: invasion, matrix metalloproteinases.
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Introduction
The interleukin (IL)-6 cytokine family comprises IL-6, IL-11,
leukaemia inhibitory factor (LIF), oncostatin M (OSM), ciliary
neurotrophic factor (CNTF) and cardiotrophin (CT-1), all of
which share the subunit glycoprotein (gp) 130 receptor (Bruce
et al. 1992;Gearing 1993;Heinrich et al. 1998). These cytokines
have been studied intensively due to their function as regulators
of cellular processes. LIF was first described as inducing dif-
ferentiation in the murine leukaemia cell line M1 (Gearing et al.
1987; Mathieu et al. 2012), whereas OSM was identified as a
growth regulator in U937 histiocytic lymphoma cells (Zarling
et al. 1986).
Several reports have demonstrated biological effects of OSM
and LIF in a variety of tissues, but these effects seem to be cell
type dependent. Although OSM inhibits growth in breast, lung,
stomach, ovary and skin tumour cell lines (Horn et al. 1990), it
may enhance cell proliferation of normal fibroblast, muscle and
endothelial cells (Grove et al. 1993). Functions of LIF in
different cell types include induction of cell proliferation, cell
differentiation and cell survival (Hilton 1992).
Both cytokines appear to be important for the normal devel-
opment of human pregnancy. In fertile women, LIF has been
detected in uterine flushings throughout the peri-implantation
period and its level increases slightly after the release of LH
(Laird et al. 1997). In addition, lif-deficient mice are infertile
due to a lack of blastocyst attachment, but fertility can be
recovered by further administration of LIF (Stewart et al.
1992). In addition, mutation of LIF receptor (LIFR) disturbs
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physiological placentation in mice (Ware et al. 1995). In wild-
type mice, OSM is transiently expressed in the luminal epithe-
lium on late Day 4 and then in the stroma at the attachment site
on Days 5–6 of pregnancy, but not in lif-null animals (Fouladi-
Nashta et al. 2005). Previous studies in humans did not detect
OSM transcripts in the endometrium (Cullinan et al. 1996).
Levels of OSM are significantly increased in serum from
pregnant compared with non-pregnant women (Ogata et al.
2000). During the first trimester of pregnancy, OSM is produced
by decidual glands and stromal cells and promotes human
chorionic gonadotrophin (hCG) release (Ogata et al. 2000).
Levels of OSM in the placenta and serum of pre-eclamptic
women are significantly higher than in normal pregnancy and
OSMexpression in the cytotrophoblast, syncytiotrophoblast and
epithelium of pre-eclamptic placentas is stronger than that of
normal placentas (Lee et al. 2009).
LIF uses LIFR-gp130, whereas OSM has two binding recep-
tor complexes consisting of OSM receptor (OSMR)-gp130 and
LIFR-gp130 (Gearing et al. 1992; Thoma et al. 1994; Liu et al.
1998; Lass et al. 2001; Garcı́a-Tuñón et al. 2008). OSM binding
to OSMR-gp130 induces Janus kinase (JAK) 2 and signal
transducer and activator of transcription (STAT) 3 phosphory-
lation (Fossey et al. 2011). Binding of LIF to its receptor
complex activates the JAK/STAT, mitogen-activated protein
kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/AKT
pathways (Aghajanova 2010). In several cell types, ERK1/2 can
be activated by LIF and OSM (Smyth et al. 2008; Prakash et al.
2011). The ERK/MAPK pathway contains a cascade of protein
kinases and regulates a variety of cellular responses, including
proliferation, differentiation, survival and apoptosis (Shaul and
Seger 2007; Wortzel and Seger 2011).
It has been reported that trophoblast invasion and placental
development are regulated by LIF (Bischof et al. 1995; Sharkey
et al. 1995; Nachtigall et al. 1996). In particular, our group has
shown that LIF enhances the invasiveness of trophoblast cells by
activation of STAT3 and downregulation of tissue-specific
inhibitors of metalloproteinase (TIMP)-1 (Fitzgerald et al.
2005; Poehlmann et al. 2005). Extravillous trophoblast (EVT)
cells invade the decidua during the first trimester of pregnancy
where they are involved in angiogenesis and vascularisation
(Lunghi et al. 2007; Bilban et al. 2010; Fitzgerald et al. 2011).
EVT invasion is a complex process that requires expression
and activation of matrix metalloproteinases (MMPs; Fitzgerald
et al. 2011; Knöfler and Pollheimer 2012). The MMPs are zinc-
dependent endopeptidases capable of degrading components
of the extracellular matrix (ECM) that are involved in physio-
logical and pathological events (Staun-Ram and Shalev 2005;
Kessenbrock et al. 2010). MMP-2 (gelatinase A) and MMP-9
(gelatinase B) are key enzymes for trophoblast invasion during
the implantation process (Staun-Ram and Shalev 2005; Cohen
et al. 2006). Activation of the STAT3 pathway leads to upre-
gulation of MMP-2 expression in tumour cells, as shown in a
melanoma cell line (Xie et al. 2004).
In the present study we used four different cells lines that are
frequently used as models for trophoblast cells but differ in
terms of proliferation rates and invasiveness. The cell lines
used in the present study were the immortalised trophoblast
cell line HTR-8/SVneo, which has been generated by sv40
Large T Antigen transfection of first-trimester EVT cells
(Graham et al. 1993), the choriocarcinoma cell line JEG-3 and
two hybrid cell lines, based on the JEG-3-derivedmutant AC1-1
cells fused with human first trimester (ACH-3P) or third
trimester (AC1-M59) trophoblast cells (Gaus et al. 1997; Hiden
et al. 2007). A previous study analysed the effects of OSM on
MMP-2 and MMP-9 expression exclusively in HTR-8/SVneo
cells, but without comparison with LIF or other cell lines (Ko
et al. 2012). Previous comparisons have demonstrated major
differences between HTR-8/SVneo cells and other trophoblast-
derived cell lines and primary trophoblast cells (Bilban et al.
2010; Morales-Prieto et al. 2012; Suman and Gupta 2012).
Therefore, the aim of the present study was to systematically
compare the effects of LIF and OSM on the activation of major
signalling pathways, as well as on invasiveness and viability, in
the four aforementioned trophoblast cell lines.
Materials and methods
Cell culture and reagents
The immortalised human trophoblast cell line HTR-8/SVneo
was cultured in RMPI-1640 medium (PAA Laboratories,
Pasching, Austria), whereas the choriocarcinoma cell line
JEG-3 and its derivatives ACH-3P and AC1-M59 were cultured
in Ham F-12 medium (PAA Laboratories). The media were
supplementedwith 10% fetal bovine serum (Sigma,Taufkirchen,
Germany), 50UmL1 penicillin and 50 mgmL1 streptomycin
(PAA Laboratories). Cell lines were maintained under standard
conditions (378C, 5% CO2, humidified atmosphere). LIF was
purchased from Millipore (Schwalbach, Germany) and OSM
was obtained from Immunotools (Friesoythe, Germany). The
STAT3 inhibitor VI, S3I-201 was obtained from Calbiochem
(Darmstadt, Germany). In all experiments, the concentration of
LIF and OSM used was 10 ngmL1. We chose this concentra-
tion for both cytokines in all experiments based on previous
experiences with LIF (Fitzgerald et al. 2005; Morales-Prieto
et al. 2013), in contrast with another study that used a twofold
higher concentration of OSM (Ko et al. 2012).
STAT3 inhibition
The STAT3 chemical inhibitor VI, S3I-201 was used to block
STAT3 phosphorylation, dimerisation and DNA binding. Cells
were seeded in six-well plates, allowed to attach overnight and
then treated with 200 mM STAT3 inhibitor for 24 h for subse-
quent Western blotting, invasion or zymography analysis.
Gel electrophoresis and Western blotting
Cells were cultured in six-well plates overnight and then stim-
ulated with LIF or OSM. Protein extracts were prepared as
follows: cells were washed with phosphate-buffered saline
(PBS) containing proteinase inhibitors (5mM b-glycero-
phosphate, 3mM MgCl2, 20mgmL
1 aprotinin, 20mgmL1
leupeptin, 5mgmL1 pepstatin A, 647 ngmL1 antipain,
10mgmL1 bestatin, 0.1mM phenylmethylsulfonyl fluoride,
1mM sodium orthovanadate; SERVA Electrophoresis,
Heidelberg, Germany). Thereafter, cells were scraped from
the bottom in lysis buffer (20mM Tris-HCl, pH 7.5, 150mM
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Na2EDTA, 1mM EGTA, 1% Triton, 2.5mM sodium pyro-
phosphate, 1mM b-glycerophosphate, 1mM Na3VO4 and
1mgmL1 leupeptin; Cell Signaling Technology, Frankfurt am
Main, Germany) supplemented with protease inhibitors, fol-
lowed by three freeze–thaw cycles. Protein concentrations
were assessed by using the Bradford method (Sigma, Munich,
Germany) and 20 mg protein extract was subjected to 9.5%
sodium dodecyl sulfate–polyacrylamide gel electrophoresis.
Resolved proteins were transferred to a nitrocellulose mem-
brane (Hybond-P; GE Healthcare, Freiburg, Germany).
Membranes were blocked with 5% defatted milk dissolved in
PBS (pH 7.4) with 0.5%Tween-20, and incubated with specific
antibodies (1 : 1000 dilution) diluted in NET-G buffer
(150mM NaCl, 5mM EDTA, 50mM Tris-HCl pH 7.4, 0.05%
Triton X-100, 0.02% Gelatin) at 48C overnight followed by
incubation with a 1 : 10 000 dilution of horseradish peroxidase
(HRP)-conjugated anti-rabbit IgG antibody for 1 h at room
temperature. Monoclonal antibodies against phosphorylated
(p-) STAT3 (tyr705), p-ERK1/2 (thr202/204), b-actin or STAT3
were purchased from Cell Signaling Technology (Danvers,
MA, USA).
Blots were developed using an enhanced chemiluminescence
(ECL) detection kit (Millipore, Schwalbach, Germany). The
intensity of Western blot bands was analysed and quantified on
an MF-ChemiBis3.2 gel documentation system using Totallab
TL100 software version 2006 (biostep, Jahnsdorf, Germany)
and normalised against b-actin.
Cell viability assay
A CellTiter96 AQ Non-Radioactive Cell Proliferation Kit
(Promega, Mannheim, Germany) was used to determine the
effect of LIF or OSM on the viability of cell lines. The colour
reaction of this assay is dependent on methylthiazole tetrazoli-
um salt (MTS) reduction through NAD(P)H-dependent oxido-
reductase enzymes, which correlates with cellular metabolic
activity. Briefly, 5000 cells were plated in 96-well microtitre
plates and cultured in medium containing 10% fetal bovine
serum (100mL per well) in the presence or absence of LIF or
OSM. After 24 h incubation, 20 mL MTS solution was added
into each well and samples were incubated for a further 1–4 h.
Absorbance was read at 490 nm on a 96-well plate reader.
Cell invasion assay
The in vitro invasion assay was performed in 24-well inserts
with porous membranes (8-mm pore size; Millipore, Schwal-
bach, Germany). Briefly, 30mL diluted Matrigel (1 : 3) was
added to the entire surface of themembrane. Coated inserts were
incubated at 378C for 30min to allow the Matrigel to solidify.
Suspensions of 1 105 cells in 200 mL were transferred to the
inserts precoated with Matrigel (BD Biosciences, Heidelberg,
Germany) and incubated with or without LIF or OSM in the
upper and lower chambers. After 24 h incubation at 378C in a 5%
CO2 atmosphere, cells in the upper chamber were removed with
a cotton swab, whereas invading cells were fixed with chilled
80% ethanol and stained with 0.1% crystal violet. After wash-
ing, cells were eluted by adding 200mL of 1% acetic acid.
Colorimetric absorbancewas detected at 570 nm and normalised
against untreated cells.
STAT3 DNA binding assay
STAT3 nuclear activation was quantified by using a TransAM
STAT family kit (Active Motif, La Hulpe, Belgium) according
to the manufacturer’s protocol. Briefly, cells were transferred
to six-well plates and treated with LIF (10 ngmL1) or OSM
(10 ngmL1) for 4 h. Nuclear protein fractions were extracted
using a Nuclear Extract Kit (Active Motif). Then, 5mg nuclear
extract was incubated for 1 h in 96-well plates coated with oli-
gonucleotides containing the STAT3 consensus binding site
(50-TTCCCGGAA-30). Active STAT3 in the nuclear extract
bound to the oligonucleotides was detected by a STAT3-
specific antibody and an HRP-conjugated secondary antibody.
After addition of the developing solution, absorbance was
measured at 450 nm, corrected to blank and normalised against
untreated cells.
Zymography
After 24 h incubation with the STAT3 inhibitor, cells were
incubated with or without LIF in serum-free medium for a fur-
ther 48 h. Finally, cells and supernatants were collected sepa-
rately. Conditioned media were concentrated by using Amicon
ultra-4 centrifugal filter devices (Millipore). Cells were lysed
with lysis buffer on ice and then sonicated for 1min. Protein
concentrations in the conditioned supernatants were determined
by the Bradford protein assay (Sigma) and equal amounts of
protein (10mg) were subjected to gel electrophoresis. Equal
amounts of protein were incubated with 5 non-reducing
loading buffer for 10min at room temperature and electro-
phoresed on 9% acrylamide gels containing 0.1% w/v gelatine
under non-reducing conditions. After two washing steps for
30minwith 2.5%TritonX-100 solution, gels were incubated for
18 h at 378C in developing buffer (50mM Tris, 200mM NaCl,
10mM CaCl2, pH 7.4). The divalent metal cation triggers
enzymatic activity of otherwise non-active pro-MMPs. Gels
were stained with Coomassie brilliant blue R-250 (0.1% w/v).
The digested areas appear clear on a blue background, corre-
lating with the protein concentration of the gelatinases, which
were quantified on an MF-ChemiBis3.2 gel documentation
system using Totallab TL100 software (biostep).
Statistical analyses
Western blots and zymography were repeated at least three
times. DNA-binding, invasion and viability assays were per-
formed independently at least three times and each experiment
comprised three independent replicates. Student’s t-tests were
used for statistical analyses. Two-sided P# 0.05 was consid-
ered significant.
Results
STAT3 and ERK1/2 expression
STAT3 and ERK1/2 were constitutively expressed at different
levels in all cell lines tested. Although ERK2 expression was
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higher than that of ERK1 in HTR-8/SVneo cells, in all chorio-
carcinoma-derived cell lines ERK1 expression was higher than
that of ERK2 (Fig. 1a; densitometry results not shown).
Effects of LIF and OSM on STAT3 and ERK1/2
phosphorylation
Slight constitutive phosphorylation of STAT3 (tyr705) was
detectable only in HTR-8/SVneo and ACH-3P cells. LIF and
OSM induced phosphorylation of STAT3 (tyr705) and ERK1/2
(thr202/204) in all analysed cell lines, but at different intensities
(Fig. 1a). LIF and OSM induced stronger STAT3 phosphory-
lation in HTR-8/SVneo cells than in ACH-3P, AC1-M59 and
JEG-3 cells (Fig. 1b). The effects of LIF and OSM did not differ
significantly, except in ACH-3P cells, where LIF induced
slightly but significantly stronger STAT3 phosphorylation
(Fig. 1b).
In general, LIF and OSM induced stronger phosphorylation
of ERK1 than ERK 2 in all choriocarcinoma-derived cell lines,
but stronger phosphorylation of ERK2 than ERK1 in HTR-8/
SVneo cells (Fig. 1c, d ). The effects ofOSMandLIF onERK1/2
phosphorylation were similar in AC1-M59 and JEG-3 cells. The
effect of OSM was significantly stronger than that of LIF on
ERK1 phosphorylation in ACH-3P cells (Fig. 1c). The effect of
OSM was also significantly stronger on ERK2 phosphorylation
in ACH-3P and HTR-8/SVneo cells (Fig. 1d ).
Effects of LIF and OSM on STAT3 DNA-binding capacity
Stimulation of all four cell lines with LIF and OSM significan-
tly increased STAT3 DNA-binding activity compared with
untreated cells (Fig. 2). In the JEG-3 derivates, LIF and OSM
induced similar levels of STAT3 DNA-binding activity,
whereas in HTR-8/SVneo cells LIF induced STAT3 DNA-
binding activity significantly stronger than OSM. In JEG-3
cells, LIF and OSM induced the highest increase in STAT3
DNA-binding activity (4.7- and 4.1-fold increases, respec-
tively). ACH-3P, HTR-8/SVneo and AC1-M59 cells were less
responsive in this respect. No further increase in STAT3 DNA
binding was observed when using 20 ngmL1 OSM in any of
the cell lines tested (data not shown).
Effects of LIF and OSM on cell invasion and viability
In our hands, neither LIF nor OSM significantly affected the
viability of any of the cell lines tested (data not shown). To
investigate the effects of LIF and OSM on invasiveness, cells
were incubated in the presence or absence of LIF (10 ngmL1)
LIF (10 ng mL1)
Control
OSM (10 ng mL1)
LIF (10 ng mL1)
Control
OSM (10 ng mL1)
LIF (10 ng mL1)
Control
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Fig. 1. Expression and phosphorylation of signal transducer and activator of transcription (STAT) 3 and extracellular signal-regulated kinase (ERK) 1/2 in
trophoblast cell lines. Cells were serum starved for 2 h and subsequently stimulated with leukaemia inhibitory factor (LIF; 10 ngmL1) or oncostatinM (OSM;
10 ngmL1) for 15min. (a) RepresentativeWestern blotmembranes for phosphorylated (p-) STAT3 (tyr705), total STAT3, p-ERK1/2 (thr202/204), total ERK1/2
and b-actin. Band intensities were assessed by densitometry and ratios between phosphorylated and respective total protein calculated. Control values were
given a value of 1. (b–d ) Relative expression of p-STAT3 (b), p-ERK1 (c) and p-ERK2 (d ). Data are the mean  s.e.m. of three independent experiments.
*P, 0.05 (Student’s t-test).
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or OSM (10 ngmL1) for 24 h in a Matrigel invasion assay.
Compared with their respective unstimulated controls, LIF
significantly enhanced invasiveness in ACH-3P (by 29%) and
JEG-3 (by 25%) cells, but not in HTR-8/SVneo or AC1-M59
cells. OSM induced a slight (and non-significant) increase in
invasiveness in HTR-8/SVneo, ACH-3P and JEG-3 cells
(Fig. 3).
Effects of STAT3 inhibition on invasion
Twenty-four hour treatment with the STAT3 inhibitor decreased
LIF-induced STAT3 expression and activation by approxi-
mately 60% and 80% in ACH-3P and JEG-3 cells, respectively,
as confirmed by Western blotting (Fig. 4a, b). Inhibition of
STAT3 phosphorylation resulted in a significant reduction in
ACH-3P and JEG-3 invasion (by 25%; Fig. 4c), but had no
effect on cell viability (Fig. 4d ).
Effects of blocking STAT3 phosphorylation on MMP-2
and MMP-9 activity
Conditioned medium and lysates fromACH-3P and JEG-3 cells
were obtained after 24 h treatment with the STAT3 inhibitor,
followed by 48 h with or without LIF. Protein levels of
pro-MMP-2 (72 kDa), active MMP-2 (62 kDa), pro-MMP-9
(92 kDa) and active MMP-9 (82 kDa) were detected by gelatine
zymography (Fig. 5a). Stimulation of ACH-3P and JEG-3 cells
with LIF significantly increased pro-MMP-2 and activeMMP-2
levels in conditioned medium from both cell lines, and pro-
MMP-9 levels only in conditioned medium from JEG-3 cells.
The pro-MMP-2 levels in cell lysates were not affected by LIF
stimulation (Fig. 5b). Inhibition of STAT3 phosphorylation
significantly decreased pro-MMP-2 and MMP-2 protein levels
in conditioned media from ACH-3P and JEG-3 cells, and pro-
MMP-9 protein levels in conditioned medium from JEG-3 cells.
Further administration of LIF could not rescue the effects of the
STAT3 inhibitor. Protein levels of pro-MMP-2 increased sig-
nificantly in lysates of both cell lines after treatment with the
STAT3 inhibitor (Fig. 5b).
Discussion
The purpose of the present study was to assess and compare the
effects of the IL-6-type cytokine family members LIF and OSM
on different trophoblast cell lines. Some effects of LIF, mainly
on JEG-3 and HTR-8/SVneo cells, have been published previ-
ously and have been repeated and confirmed here as a com-
parison for the effect of OSM. Stimulation with LIF and OSM
induced STAT3 (tyr705) and ERK1/2 phosphorylation and
STAT3 DNA binding in all cell lines tested. These results
suggest that LIF andOSM transduce their effects via their shared
common receptor unit gp130, which is known to activate these
pathways (Plun-Favreau et al. 2003). LIF and OSM induced
similar levels of STAT3 phosphorylation in the cell lines tested,
except for HTR-8/SVneo cells, where the effects appear to be
slightly stronger (effects summarised in Table 1).
In our hands, LIF and OSM had no significant effect on cell
viability in any of the cell lines tested, as assessed by the MTS
assay, which analyses metabolic activity in a cell culture. These
results after 24 h cell culture seem to disagree with previously
published results from our group, whereby 10 ngmL1 LIF was
found to increase the proliferation in JEG-3 cells as assessed by
cell counting after 72 h (Fitzgerald et al. 2005). However, the
time frames differ between the two studies and the two methods
used to determine viability work with different parameters,
which may lead to diverse results, as shown previously (Strober
2001; Berridge et al. 2005; Wang et al. 2010; Hoskins et al.
2012). Results derived from the MTS assay serve as a control to
exclude the influence of cell viability on invasion.
LIF and OSM triggered the phosphorylation of ERK1 and
ERK2. The expression pattern of p-ERK1/2 in HTR-8/SVneo
cells differed from that in choriocarcinoma-derived cell lines.
LIF (10 ng mL1)
Control























Fig. 3. Effects of leukaemia inhibitory factor (LIF) and oncostatin
M (OSM) on the invasiveness of trophoblast cell lines, assessed with
a Matrigel invasion assay. Cells were incubated with or without LIF
(10 ngmL1) or OSM (10 ngmL1) for 24 h. Staining of invaded cells
was assessed by measuring absorbance on a plate reader. Control values
were given a value of 1; values from other groups are expressed relative to
the control group. Data are the mean s.e.m. of three independent experi-
ments. *P, 0.05 compared with control (Student’s t-test).
LIF (10 ng mL1)
Control





































Fig. 2. DNA binding activity of signal transducer and activator of
transcription (STAT) 3 upon stimulation with leukaemia inhibitory factor
(LIF) or oncostatin M (OSM). Trophoblast cell lines were starved for 2 h
and subsequently treated in presence or absence of LIF (10 ngmL1) or
OSM (10 ngmL1) for a further 4 h. The nuclear fraction was extracted
and analysed for STAT3 DNA-binding capacity by using an ELISA-based
colorimetric assay kit. Samples were measured at an optical density of
450 nm. Control values were given a value of 1; values from other groups are
expressed relative to the control group. Data are the mean s.e.m. of nine
independent experiments. *P, 0.05 compared with control or as indicated
(Student’s t-test).
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After treatment with LIF or OSM, phosphorylation of ERK2
was higher than that of ERK1 inHTR-8/SVneo cells, whereas in
the choriocarcinoma-derived cell lines levels of p-ERK1 were
higher. Only in ACH-3P cells did OSM induce a more intensive
phosphorylation of ERK1/2 than LIF. Previously, we reported
that inhibition of ERK by U0126 significantly decreased JEG-3
and HTR-8/SVneo proliferation and increased JEG-3 invasive-
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Fig. 4. Effects of signal transducer and activator of transcription (STAT) 3 inhibition on invasion and viability of ACH-3P and JEG-3 cells. ACH-3P cells
and JEG-3 cells were pretreated or not with a STAT3 inhibitor (200 mM) for 24 h. Subsequently, STAT3 phosphorylation (tyr705) was analysed by Western
blotting, and Matrigel invasion and methylthiazole tetrazolium salt (MTS) viability assays were performed. (a) Representative Western blots checking
STAT3 inhibitor efficacy. Before lysis, cells were stimulated with leukaemia inhibitory factor (LIF) for 15min to induce STAT3 phosphorylation. (b) Band
intensities were assessed by densitometry. Applied concentrations as in (a). (c) For assessment of invasiveness, cells were placed in the upper chamber of
Matrigel coated wells on a transwell plate and exposed or not to LIF (10 ngmL1) for 24 h. The invading cells were stained and intensity was quantified on a
plate reader. (d ) For assessment of viability, cells were cultured in 96-well plates for a further 48 h. Relative viability was assessed using an MTS assay and
colorimetric analysis on a plate reader. Data are the mean s.e.m. of three independent Western blotting experiments and nine viability and invasion assays.
*P, 0.05 (Student’s t-test).
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Fig. 5. Effects of signal transducer and activator of transcription (STAT) 3 inhibition onmatrixmetalloproteinase (MMP)-2 andMMP-9 activity
in conditionedmedium and cell lysates. ACH-3P and JEG-3 cells were pretreatedwith or without the STAT3 inhibitor (200 mM) for 24 h, followed
by stimulation with or without leukaemia inhibitory factor (LIF; 10 ngmL1) in serum-free medium for 48 h. Media and cell lysates were
collected, concentrated and (a) MMP-2 and MMP-9 activity was assessed by gelatin zymography. (b) Densitometric analyses of zymography
bands. The intensity of control samples was given a value of 1; values from other groups are expressed relative to the control group. Data are the
mean  s.e.m. of three independent assays. *P, 0.05 (Student’s t-test).
Table 1. Summary of the effects of leukaemia inhibitory factor and oncostatin M on trophoblast cells
m, increased; mm, significantly increased; n.c., not changed; p-, phosphorylated; STAT3, signal transducer and activator of transcription; ERK, extracellular
signal-regulated kinase; LIF, leukaemia inhibitory factor; OSM, oncostatin M
Cell line p-STAT3 p-ERK1 p-ERK2 STAT3 DNA binding Viability Invasion
LIF OSM LIF OSM LIF OSM LIF OSM LIF OSM LIF OSM
HTR-8/SVneo mm mm mm mm mm mm mm mm n.c. n.c. n.c. m
ACH-3P mm mm mm mm m mm mm mm n.c. n.c. mm m
AC1-M59 mm mm mm mm m mm mm mm n.c. n.c. n.c. n.c.
JEG-3 mm mm mm mm m m mm mm n.c. n.c. mm m
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Invasion of trophoblast cells into the decidua is essential
for successful implantation and placentation (Knöfler and
Pollheimer 2012). Several factors control this process, including
cytokines, adhesion molecules and ECM-degrading enzymes
(Goldman-Wohl and Yagel 2002; Knöfler and Pollheimer
2012). MMPs are not only involved in ECM degradation under
pathological conditions, but are also associated with trophoblast
invasion in pregnancy, especiallyMMP-2 andMMP-9,which are
mainly produced by EVT and villous cytotrophoblast, respec-
tively (Cohen et al. 2006; Demir-Weusten et al. 2007). Recently,
it was reported that 20 ngmL1 OSM stimulated the invasion of
HTR-8/SVneo cells by increasing MMP-2 and MMP-9 levels
(Ko et al. 2012). The results of the present study indicate that
10 ngmL1 OSM slightly increases the invasiveness of all cells
lines, whereas 10 ngmL1 LIF induces a significant increase in
the invasiveness of ACH-3P and JEG-3 cells.
In the present study, the invasiveness of HTR-8/SVneo was
not significantly induced by either LIF or OSM. It can be argued
that the concentrations used in the present study were lower than
in other studies; for example, Suman et al. (2013) found that
50 ngmL1 LIF increased the invasion of HTR-8/SVneo cells.
Nevertheless, the concentrations used in the present study
enhanced the invasiveness of the choriocarcinoma-derived cell
lines JEG-3 and ACH-3P, which is in line with a previous report
(Morales-Prieto et al. 2013). Conversely, it can be argued that
the origin of HTR-8/SVneo cells may be responsible for this
cellular response. The HTR-8/SVneo cell line is an immorta-
lised cell line exhibiting a highly invasive phenotype that may
not be further enhanced by comparatively low concentrations of
LIF and OSM.
The release of MMP-2 and MMP-9 from trophoblastic cells,
including from first-trimester EVT (Tapia et al. 2008) and
HTR-8/SVneo cells (Busch et al. 2009), has been demon-
strated previously. After 24 h stimulation of EVT with LIF,
Tapia et al. (2008) did not find any increases in MMP release,
whereas in the present study LIF induced significant MMP
release by ACH-3P and JEG-3 cells after 48 h. In lysates from
ACH-3P and JEG-3 cells, pro-MMP-2 protein levels increased
after STAT3 inhibition, whereas active MMP-2 was not detect-
able. This means that the non-active form accumulates in the
cells when STAT3 is inhibited. Simultaneously, LIF-induced
MMP-2 and MMP-9 release into the medium was significantly
reduced in both cell lines, although MMP-9 isoforms were not
detectable in cell lysates. These results are in line with previous
studies in other cell models demonstrating that STAT3 seems to
be involved in the LIF-induced MMP release; for example, in
fibroblasts it activates MMP-9 release (Wang et al. 2007).
In ovarian cancer cells, inhibition of STAT3 led to a decrease
in MMP-2 activity in cell culture supernatant (Seo et al. 2012).
Additional LIF could not reverse the effects of STAT3 inhibi-
tion on MMP-2 and MMP-9 expression. These results imply
that LIF enhances MMP-2 and MMP-9 secretion exclusively
through STAT3.
Conclusion
In trophoblast cell lines, OSM shares STAT3 and ERK1/2 sig-
nalling with LIF, as well as the capacity to induce invasiveness
through activation of MMP-2 and MMP-9. Physiologically,
in utero, these cytokines may act synergistically or cross-
compensate for deficiencies. Their functions differ slightly,
which indicates the involvement of further intracellular cas-
cades, potentially activated through the different gp130 receptor
subunits.
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a b s t r a c t
Background: MicroRNAs (miRNAs) are small single-stranded RNA molecules working as post-
transcriptional modulators of gene expression. Trophoblast cells are a heterogenous group of fetal cells
forming the fetoematernal interface and displaying a wide spectrum of functions. The regulation of their
behavior may partly underly the control through miRNAs. Therefore, we aimed to compare the miRNA
profile of primary first and third trimester trophoblast cells with that of different trophoblastic cell lines.
Material and methods: Total RNA was obtained from isolated cytotrophoblast cells from healthy term and
first trimester placentae and the cell lines HTR-8/SVneo (immortalized trophoblast cells), JEG-3
(choriocarcinoma), ACH-3P and AC1-M59, which are choriocarcinoma cells fused with first and third
trimester trophoblast cells, respectively. The expression level of 762 different miRNAs was quantitatively
analyzed by using a TaqMan Human MicroRNA Array. For testing the reproducibility of the array tech-
nique, the expression of 9 selected miRNAs has been re-analyzed by individual qPCR.
Results: The analyzed cell types share many similar patterns of miRNAs, but are significantly distinct in
the expression of three miRNA clusters: chromosome 19 miRNA cluster (C19MC; containing 54 different
miRNAs), C14MC (34 miRNAs) and a minor cluster (miRNA-371 to miRNA-373 cluster), also located on
chromosome 19. Expression of miRNAs within C19MC increases significantly from first to third trimester
trophoblast while that of C14MC members decreases. MiRNAs within the miR-371-3 cluster augment
slightly. C19MC and the miR-371-3 cluster are not expressed by HTR-8/SVneo cells whilst C14MC is
almost not detectable in the choriocarcinoma-derived cell lines complete array data available at NCBI
Gene Expression Omnibus accession number GSE32346: http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc¼GSE32346). Beside the miRNAs within the mentioned clusters, further 27 miRNAs are differ-
entially expressed (>100 fold) between term and first trimester trophoblast cells. The placenta-specific
miRNAs miR-141 and miR-21 as well as let-7g are expressed in all tested cells with the highest expression
in primary trophoblast cells.
Conclusion: Primary first trimester and term trophoblast cells and trophoblastic cell lines display major
differences in their miRNA fingerprints which may be involved in their different behavior and
characteristics.
 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Since the discovery of the first microRNA lin-4 in 1993 [1], the
study of microRNAs (miRNAs) has generated great interest due to
their vast potential in the regulation of protein-coding genes.
MiRNAs are highly conserved sequences of single-stranded RNA
(w19e22 nt) which repress gene expression by a mechanism
involving the RNA interference pathway [2]. Depending on the
complementary grade between themiRNA and its mRNA target, the
pathway results in inhibition of translation, or cleavage of the target
mRNA, when partially or fully complimentary, respectively [3]. This
characteristic allows targeting of several genes simultaneously and
therefore, it is expected that 30% of the human genome may be
regulated by miRNAs [4].
Remarkably, miRNA genes are frequently located at fragile sites
and cancer-related genomic regions [5], and tend to be organized
into clusters suggesting that miRNAs belonging to a same cluster
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are likely to have similar functions and be regulated by the same
promoter and in the same transcriptional orientation [6,7]. The
analysis of the miRNA signature (miRNome) in normal human
tissues revealed some universally expressed miRNAs but also
several groups of miRNAs exclusively or preferentially expressed in
a tissue-specific manner [8]. Likewise, the miRNA expression
signature is frequently altered in cancer [9,10], and can be used to
distinguish between cancer and normal tissues [11,12] or even to
identify poorly differentiated tumors [13].
Recent reports have described two large miRNA clusters
expressed in placenta: The chromosome 19miRNA cluster (C19MC),
which maps to chromosome 19q13.41 and comprises 54 predicted
miRNAs, 43 of which have been already cloned and sequenced
(reviewed in Ref. [3]); and the C14MC located in the 14q32 domain
and which contains 34 miRNAs [14]. C19MC is exclusively found in
primates while C14MC appears to be conserved among all euthe-
rian species [15]. Both are encoded within imprinted domains:
C19MC is expressed from the paternally inherited chromosome
whilst C14MC is expressed from the maternally inherited chro-
mosome [14,15]. Imprinted genes are known to be involved in
human embryonic development and to play important roles in the
regulation of cellular differentiation and fate [16].
The signature of miRNAs in trophoblast cells is largely unknown.
Initial investigations identified somemiRNAs specifically expressed
in placenta tissue and released into maternal plasma [17]. Further
analyses of the expression of small RNAs in placenta by small RNA
library sequencing confirmed that most placenta-specific miRNAs
were linked to the C19MC cluster and demonstrated that villous
trophoblast cells express such miRNAs [18]. Recent reports have
quantitatively analyzed the expression of up to 820 miRNAs in
placenta tissue samples collected in the first or third trimester
[19,20]. Interestingly, the concentration of pregnancy-associated
miRNAs increased throughout pregnancy [19] and was altered in
placentas from pregnancies with preeclampsia or preterm labor
[20]. These results suggest miRNAs as potential serum markers for
the normal function of the placenta. However, little is known about
the cellular origin of these placental miRNAs.
The study of the miRNome of isolated trophoblast cells is
restricted by the limitations associated with primary cells such as
relatively low number of isolated cells, short lifespan or lack of
proliferation in vitro [21]. Therefore, during the last three decades,
several trophoblastic cell lines have been established attempting to
resemble primary trophoblasts and avoiding the limitations of
isolation. Twomainmethodologies have been used: Introduction of
the gene encoding simian virus 40 large T (sv40T) antigen [22] or
establishment of human choriocarcinoma cell lines [23]. Therefore,
the different genetic background and the methods used for
immortalization should be taken into consideration for interpreta-
tion and discussion of results obtained from the respective cell line.
To our knowledge, there is a very limited number of publications
on miRNA expression profiles in trophoblastic cell lines, or their
comparison with primary isolated trophoblast cells [24]. To over-
come this lack of knowledge, we assessed the miRNA expression
patterns of four cell lines and isolated trophoblast cells from first
and third trimester placentae. We included the immortalized
human first trimester trophoblast cell line HTR-8/SVneo [22], the
choriocarcinoma cell line JEG-3 and the two hybrids cell lines, ACH-
3P and AC1-M59, which resulted of fusion of the AC-1 choriocar-
cinoma cell line with first and third trimester isolated trophoblast
cells, respectively [23,25].
For confirmation of array results, expression of 9 individual
miRNAs was assessed by qPCR. Instead of random choice, we
selected five miRNAs representing the C19MC (miR-518a-5p and
miR-519e), the C14MC (miR-411 and miR-539) and the miR-371-3
cluster (miR-373); as well as four miRNAs that have been
previously described to be expressed in placenta or tumors: miR-9,
miR-21, miR-141, and let-7g [3,14,17,18,26].
By fingerprinting miRNA gene expression we aimed to
contribute to better understanding of differences and resemblances
of these frequently used cell lines and primary trophoblast cells.
Concluding from our observations, the above mentioned cluster
C14MC and C19MC may play key roles in regulating their pheno-
typical and functional diversity.
2. Materials and methods
2.1. Cell lines
Four cell lines were investigated in this study: the immortalized extravillous first
trimester trophoblast cell line HTR-8/SVneo (kind gift from CH Graham, Kingston
Canada) [22], the choriocarcinoma cell line JEG-3 (DSMZ, Braunschweig, Germany),
and two hybrids of AC-1 choriocarcinoma cells (derived from JEG-3 by mutagenesis)
with human first and third trimester trophoblast cells, ACH-3P and AC1-M59 cells,
respectively (kind gift from G Desoye, Graz, Austria) [23,25,27].
2.2. Cell culture
Cell cultures were performed at 106 cells/175 cm2 flask, and maintained under
standard conditions (37 C, 5% CO2, humid atmosphere) in Ham’s F-12 Nutrient
Mixture with L-glutamine (GIBCO, Paisley, UK) or RPMI Medium (GIBCO) (HTR-8/
SVneo cells) supplemented with 10% heat-inactivated fetal calf serum (FCS; GIBCO)
and 1% penicillin/streptomycin antibiotic solution (GIBCO).
2.3. Primary trophoblast isolation protocol
Healthy term placentae were obtained from the Department of Obstetrics,
University Hospital, Jena, Germany. First trimester placentae have been received
after elective pregnancy termination at week 8e12 from the Department of Gyne-
cology of the Robert-Koch-Hospital, Apolda, Germany. Trophoblast isolation was
performed using a modified Kliman method as described in detail by Stenqvist et al.
[28]. Briefly, placental tissue was physically disaggregated and enzymatically
digested for 30 min. After washing, isolated cells were applied on a density gradient
(Percoll, Pharmacia, Sweden) and the fraction retained within the layer of 25%
Percoll was collected and washed. For depletion of non-trophoblastic cells, Dyna-
beads coated with anti-CD45 and anti-CD82 antibodies (Life Technologies, Darm-
stadt, Germany) were used. Before use for RNA isolation, isolated cells have been
cultured in F-12 medium (GIBCO) supplemented with 10% FCS for two days, and
remaining non-adherent cells have been removed. Adherent cells have been
checked for purity by flow cytometry using anti-EGF-receptor, anti-cytokeratin-7,
and anti-HLA-G antibodies. The levels of impurity (cells negative for mentioned
markers) did not exceed 10%.
2.4. RNA isolation and array analysis
Cells were seeded in 12-well plates, allowed to attach overnight and serum
deprived for at least 2 h. Total RNAwas isolated by using a mirVana isolation kit (Life
Technologies, Darmstadt, Germany), according to the manufacturer’s protocol.
Thereafter, 100 ng of total RNA containing miRNAs was reverse transcribed using the
specific Megaplex RT primers (Life Technologies) followed by a pre-amplification of
the obtained cDNAs. Finally, the expression level of 762 different miRNAs was per-
formed using the TaqMan Array Human MicroRNA A þ B Cards Set v3.0 (Life
Technologies) on a 7900 Real Time PCR System (Applied Biosystems). Card A
includes miRNAs, which tend to be defined and broadly or highly expressed, whilst
those of card B are less extensively studied or expressed at low levels (suppliers
product description). Experimental data were analyzed by DataAssist v3.0 (Life
Technologies) using RNU48 and RNU44 as endogenous controls. The amplification
efficiency for TaqMan gene expression assays has been tested and described by the
manufacturer in detail (Application Note, Applied Biosystems). It reaches 100%
(10%). Due to software settings, results from card A and card B had to be analyzed
separately and are displayed as heatmaps from unsupervised hierarchical clustering
of all miRNAs and all individual samples. The arrays were repeated independently
twice for ACH-3P, AC1-M59 cells and HTR-8/SVneo, and three times for JEG-3 and
trophoblast cells.
2.5. Real-time quantitative RT-PCR
The expression levels of five miRNAs (miR-518a-5p, miR-519e, miR-373, miR-
411, miR-539) representing three different miRNA clusters (C19MC, cluster miR-
371-3, C14MC) were confirmed by applying individual TaqMan miRNA Assays
(Applied Biosystems, Foster City, CA, USA) according to the protocol provided by the
supplier. Additionally, the expression of another set of 4 miRNAs (miR-9, miR-21,
miR-141, let-7g), which are known to correlate with tumor-grade, to be implicated
D.M. Morales-Prieto et al. / Placenta 33 (2012) 725e734726
in pregnancy or to be related with members of the intracellular signaling cascade of
LIF was confirmed by use of the same method [26]. Total RNA was isolated by using
a mirVana isolation kit (Life Technologies). RNA purity was assessed by the ratio of
spectrophotometric absorbance at 260 and 280 nm (A260/280 nm) on a NanoDrop
ND-1000 (NanoDrop Inc, Wilmington, DE USA). Reverse transcription was per-
formed with miRNA specific stem-loop RT primers and TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems), followed by qRT-PCR using specific TaqMan
Assays and TaqMan Universal PCR Master Mix. All reactions were run in duplicates
including no-template controls in 96-well plates on a 7300 Real Time PCR System
(Applied Biosystems). Fold changes were calculated by the formula 2 DDCt relative
to the expression in primary first trimester trophoblast cells. RNU48 has been used

































































Fig. 1. Unsupervised hierarchical clustering analysis of miRNAs expression profiles of all individually analyzed samples and miRNAs. The level (Ct-value) of miRNA expression is
color-coded. Red: higher miRNA expression; blue: lower miRNA expression. A) and B) represent the 381-containing miRNA assays A and B, respectively. C) and D) Zoom into the
boxes marked in A), which display expression of miRNAs with highly different expression between HTR-8/SVneo and the other cells. MiRNAs which belong to C19MC are underlined
in purple, to C14MC in green and to cluster 371e373 in blue. E) Dendograms of the unsupervised hierarchical clustering of Assay A after exclusion of data from the leading clusters.
(For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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in our model compared with RNU44 and MammU6. In our analyses (n ¼ 18) the Ct-
values for RNU48 varied between 20.81 and 23.72 (mean 21.76; SD 0.72). The
experiments were repeated independently three times and differences in the
quantified gene expressionwere statistically assessed by using a Student’s t-test and
considered statistically significant when p < 0.05.
3. Results
3.1. Expression profiles of miRNAs in isolated trophoblast cells and
cell lines
We assessed the complete (miRBase v13.0) microRNA expres-
sion profile of the four trophoblastic cell lines HTR-8/SVneo, JEG-3,
AC1-M59 and ACH-3P as well as that of trophoblast cells isolated
from first and third trimester placentae (complete array data are
accessible trough GEO Series accession number GSE32346; http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc¼GSE32346).
The detection of the total of 762 miRNAs was performed on two
different array cards A and B containing 381 miRNAs each. Around
65% of the miRNAs on card A were notably expressed (Ct < 35.0) in
any analyzed cell type, but only approximately 35% of those on card
B (Fig. 1AeB).
Unsupervised cluster analysis of all Ct-values revealed that in
both arrays (card A and B) isolated trophoblast cluster closely
together in neighbored branches of the dendogram, while cell lines
were more distant. This analysis was also able to discriminate
between first and third trimester samples, except for one sample of
third trimester trophoblast cells which had a generally low miRNA
expression. The analysis of card A also demonstrated that
choriocarcinoma-derived cell lines cluster together, whilst HTR-8/
SVneo cells appear in a different branch of the dendogram (Fig. 1A).
This was not observed on Card B, but in general the expression of
miRNAs detected on this card was low, and therefore, the informa-
tion may not be sufficient to discriminate between cell lines.
Similarly, by unsupervised hierarchical clustering of the micro-
RNA signatures we identified two major groups of microRNAs, one
of which highly expressed in the choriocarcinoma-derived cells and
term trophoblast cells, and the other one highly expressed in HTR-
8/SVneo cells and expressed by trophoblast cells but almost absent
in the choriocarcinoma-derived cells (Fig. 1C and D). A deeper
Table 1
Sequences and chromosome localization of miRNAs with >100 fold-change in HTR-8 cells compared with JEG-3 cells. All of them have been found within the marked
unsupervised hierarchically calculated clusters of cards A and B in Fig. 1 and belong to C14MC, C19MC, C19 or the let-7 family.
Up-regulated miRNA (>100-fold) in HTR-8/SVneo versus JEG-3 cells Down-regulated miRNA (>100-fold) in HTR-8/SVneo versus JEG-3 cells
miRNA Sequence (50e30) Locus miRNA Sequence (50e30) Locus
miR-127-3p UCGGAUCCGUCUGAGCUUGGCU C14MC miR-371-3p AAGUGCCGCCAUCUUUUGAGUGU C19
miR-134 UGUGACUGGUUGACCAGAGGGG C14MC miR-372 AAAGUGCUGCGACAUUUGAGCGU C19
miR-136* CAUCAUCGUCUCAAAUGAGUCU C14MC miR-373 GAAGUGCUUCGAUUUUGGGGUGU C19
miR-299-5p UGGUUUACCGUCCCACAUACAU C14MC miR-512-3p AAGUGCUGUCAUAGCUGAGGUC C19MC
miR-337-5p GAACGGCUUCAUACAGGAGUU C14MC miR-512-5p CACUCAGCCUUGAGGGCACUUUC C19MC
miR-369-5p AGAUCGACCGUGUUAUAUUCGC C14MC miR-515-3p GAGUGCCUUCUUUUGGAGCGUU C19MC
miR-370 GCCUGCUGGGGUGGAACCUGGU C14MC miR-515-5p UUCUCCAAAAGAAAGCACUUUCUG C19MC
miR-376a AUCAUAGAGGAAAAUCCACGU C14MC miR-516a-5p UUCUCGAGGAAAGAAGCACUUUC C19MC
miR-379 UGGUAGACUAUGGAACGUAGG C14MC miR-516b AUCUGGAGGUAAGAAGCACUUU C19MC
miR-382 GAAGUUGUUCGUGGUGGAUUCG C14MC miR-517a AUCGUGCAUCCCUUUAGAGUGU C19MC
miR-409-3p GAAUGUUGCUCGGUGAACCCCU C14MC miR-517* CCUCUAGAUGGAAGCACUGUCU C19MC
miR-410 AAUAUAACACAGAUGGCCUGU C14MC miR-517b UCGUGCAUCCCUUUAGAGUGUU C19MC
miR-411 UAGUAGACCGUAUAGCGUACG C14MC miR-517c AUCGUGCAUCCUUUUAGAGUGU C19MC
miR-431 UGUCUUGCAGGCCGUCAUGCA C14MC miR-518b CAAAGCGCUCCCCUUUAGAGGU C19MC
miR-487b AAUCGUACAGGGUCAUCCACUU C14MC miR-518c CAAAGCGCUUCUCUUUAGAGUGU C19MC
miR-539 GGAGAAAUUAUCCUUGGUGUGU C14MC miR-518c* UCUCUGGAGGGAAGCACUUUCUG C19MC
miR-541 UGGUGGGCACAGAAUCUGGACU C14MC miR-518d-5p CUCUAGAGGGAAGCACUUUCUG C19MC
miR-543 AAACAUUCGCGGUGCACUUCUU C14MC miR-518e AAAGCGCUUCCCUUCAGAGUG C19MC
miR-654-5p UGGUGGGCCGCAGAACAUGUGC C14MC miR-518e* CUCUAGAGGGAAGCGCUUUCUG C19MC
miR-758 UUUGUGACCUGGUCCACUAACC C14MC miR-518f GAAAGCGCUUCUCUUUAGAGG C19MC
miR-889 UUAAUAUCGGACAACCAUUGU C14MC miR-518f* CUCUAGAGGGAAGCACUUUCUC C19MC
miR-1247 ACCCGUCCCGUUCGUCCCCGGA C14 miR-519a AAAGUGCAUCCUUUUAGAGUGU C19MC
let-7b UGAGGUAGUAGGUUGUGUGGUU C22 miR-519b-3p AAAGUGCAUCCUUUUAGAGGUU C19MC
let-7d AGAGGUAGUAGGUUGCAUAGUU C9 miR-519c-3p AAAGUGCAUCUUUUUAGAGGAU C19MC
let-7e UGAGGUAGGAGGUUGUAUAGUU C19 miR-519d CAAAGUGCCUCCCUUUAGAGUG C19MC
let-7g UGAGGUAGUAGUUUGUACAGUU C3 miR-519e AAGUGCCUCCUUUUAGAGUGUU C19MC
let-7c UGAGGUAGUAGGUUGUAUGGUU C21 miR-519e* UUCUCCAAAAGGGAGCACUUUC C19MC
let-7f UGAGGUAGUAGAUUGUAUAGUU C9 miR-520a-3p AAAGUGCUUCCCUUUGGACUGU C19MC
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analysis revealed that 19 out of the 36 miRNAs belonging to this
second group map to chromosome 14 (underlined miRNAs in
Fig. 1D). In contrast, 34 out of the 42 miRNAs highly expressed in
JEG-3 cells and its hybrids belong to the placenta-specific cluster
C19MC, and 3 miRNAs to the miR-371-3 cluster, both encoded in
chromosome 19 (Fig. 1C underlined miRNAs). Isolated first and
term trophoblast cells express members of all three mentioned
miRNA clusters, but at different levels (see below).
For deeper investigation of miRNAs differing between cell lines,
those miRNAs with a fold change higher than 100-fold between
HTR-8/SVneo cells and JEG-3 cells were further statistically evalu-
ated. Thereof, 22 miRNAs belong to C14MC and are upregulated in
HTR-8/SVneo cells while 42 miRNAs belong to C19MC and were
downregulated in HTR-8/SVneo cells (Table 1).
Because of their large expression differences between the cell
lines, miRNAs within C14MC and C19MC dominate the unsuper-
vised clustering of analyzed samples. The dendogram is mainly
organized depending on the statistical power of these principle
components. In order to investigate the relevance of further miR-
NAs, which do not belong to C14MC or C19MC, the unsupervised
hierarchical clusteringwas repeated after depleting their respective
results. When only C14MC miRNAs were excluded, the order of the
resulting dendogram was the same as the original (Fig. 1E). When
C19MC miRNAs were excluded, trophoblast cells appear in a sepa-
rate branch of the dendogram and closely associated with HTR-8/
SVneo cells, which demonstrates that miRNAs belonging to the
C19MC are the principle components for the observed similarities
between choriocarcinoma-derived cell lines and isolated tropho-
blast cells (Fig. 1E). The depletion of the combination of both,
C19MC and C14MC miRNAs data, did not result in additional
changes (Fig. 1E). These results highlight on the one hand the
leading relevance of C19MC in distinction of the analyzed cell types,
but on the other hand, that the fingerprints and differences
between the different analyzed cell types do not depend exclu-
sively on C19MC and C14MC miRNAs.
3.2. MicroRNA of first and third trimester isolated trophoblast cells
MiRNAs exhibiting fold changes higher than 100 between first
and third trimester trophoblast cells, were selected for more
detailed statistical analysis: 15 miRNAs were upregulated and 31
downregulated in trophoblast cells isolated from term placentae
(Table 2). In the group of the downregulated miRNAs, 16 miRNA
map on chromosome 14 suggesting a strong decrease of the gene
expression of C14MC with gestational age (Table 2). We further
focussed on the development of the expression of all miRNAs
belonging to C14MC and C19MC from first to third trimester
trophoblast cells. A total of 93 miRNAs in both clusters were
differentially expressed (Fig. 2AeB). Fourty-six out of 47 miRNAs
belonging to C19MC were upregulated (>50%) in third trimester
trophoblasts, while 34 of 46 miRNAs belonging to C14MC were
downregulated (>50%; Fig. 2).
4. Expression of selected miRNAs confirmed by qPCR
For confirmation of array results, we analyzed by qPCR indi-
vidually the expression of 2 miRNAs representing C14MC (miR-411
and miR-539), 2 miRNAs representing C19MC (miR-519e and miR-
518a-5p) and miR-373, a member of the miR-371-3 cluster. In
agreement with the arrays, the expression of themiRNAs belonging
to C19MC increases from first to third trimester, while the
expression of members of C14MC decreases.
As observed in the arrays, HTR-8/SVneo cells differ significantly
in the expression of the miRNAs located on the chromosome 19.
The levels of miR-518a-5p, miR-519e and miR-373 were 128-,
704.3-, and 79.9-fold higher, respectively, in first trimester
trophoblast cells than in HTR-8/SVneo cells, but lower than in all
choriocarcinoma-derived cell lines (Fig. 3).
In contrast, the expression of miR-539 in HTR-8/SVneo cells was
30.7-fold higher than in first trimester trophoblast cells, but only
slightly different from the choriocarcinoma-derived cells. Notably
the expression of miR-411 in 1st trimester trophoblast cells was very
high and more similar to that in HTR-8/SVneo rather than to other
cell lines. In general, the expression of thementionedmicroRNAswas
very similar between the JEG-3 cells and its hybrids ACH-3P (JEG-3
derivates fused with 1st trimester trophoblast) and AC1-M59 (JEG-3
derivates fused with 3rd trimester trophoblast). However, a slight
increase in the expression ofmiR-373 (>75%), aswell as a decrease in
miR-539 (>80%) and miR-411 (>50%) was observable in AC1-M59
cells compared to ACH-3P cells (Fig. 3). These changes are similar to
those in trophoblast cells from 1st to 3rd trimester suggesting that
the expression of these miRNAs in the fusion-derived cell lines may
reflect the respective development stage of the underlying tropho-
blast cells used for the generation of both cell lines.
Additionally, the expression of 4 further miRNAs which may be
related with pregnancy or cancer has been analyzed by qPCR. The
results correlate with the array in the up- or down-regulation of the
genes but some differences in the fold change values were observed
(GEO GSE32346 and Fig. 3).
The expression of all four miRNAs was higher in 3rd than in 1st
trimester trophoblast cells, but the differences are little and only in
miR-141 a fold-change higher than 2 was observed. The expression
of miR-9 was higher in all cell lines compared to primary tropho-
blast cells while that of miR-141 was significantly lower in all cell
lines. The expression of miR-21 and let-7g in JEG-3 and its hybrids
was very similar and significantly lower than in HTR-8/SVneo cells.
Table 2
MiRNAs differentially expressed between isolated first and third trimester tropho-
blast cells. Listed are all miRNAs exhibiting >100-fold change.
miRNAs>100 fold changing in third trimester versus first trimester trophoblast
Up-regulated Down-regulated
miRNA Fold change Chr miRNA Fold change Chr
miR-571 30,254.01 4 miR-431 0.0002 14
miR-1178 22,925.07 12 miR-382 0.0004 14
miR-302a 5583.75 4 miR-654-5p 0.0006 14
miR-183# 2773.31 7 miR-23b 0.0008 9
miR-211 1220.31 15 miR-22 0.0011 17
miR-584 1009.38 5 let-7f 0.0015 X
miR-648 771.11 22 miR-505 0.0017 X
miR-663B 361.99 2 miR-7# 0.0023 17
miR-518f# 142.77 19 miR-337-3p 0.0024 14
let-7f-1# 119.21 9 miR-876-5p 0.0028 9
miR-208b 117.06 14 miR-501-5p 0.0033 X
miR-144 115.12 17 miR-376b 0.0037 14
miR-524-5p 114.25 19 miR-409-5p 0.0041 14
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4.1. Expression ofmiRNAs in first and third trimester trophoblast cells
resembles choriocarcinoma cell lines more than HTR-8/SVneo cells
Finally, we compared the expression of those miRNAs with the
lowest Ct-values in first and third trimester trophoblast cells with
that in cell lines. Twenty miRNAs exhibiting the lowest Ct-values,
each in first and third trimester trophoblast cells, were selected
for this analysis. This miRNA selection from primary first trimester
trophoblast cells map on a variety of chromosomes including 3
miRNAs on chromosome 19, whereas 8 out of the 20 highest
expressed miRNA in third trimester trophoblast cells are located on
chromosome 19. The heatmap demonstrates that the expression of
many of the selected miRNAs have a lower expression in HTR-8/
SVneo than the other cell lines (Table 3).
5. Discussion
Recent studies indicate that miRNA expression signatures may
be useful for the characterization and prediction of cancer [13], but
the investigation of their physiological role in pregnancy and their
possible involvement in pregnancy disorders are still incipient. The
expression of individual miRNAs as well as miRNA clusters is
regulated in a tissue-specific manner. Within its complex organ
specific miRNA signature, the placenta expresses the twomicroRNA
clusters C19MC and C14MC. Both are almost placenta-specific, but
are also expressed in brain [3,8,19]. Serum levels of some of the
C19MC members are altered in preeclampsia [8,20,29]. However,
the cellular origin of these miRNAs or their role in the control of




















































































































































































































































































































































































































































































































Fig. 2. Relative expression (fold change) of miRNAs belonging to C19MC and C14MC clusters in third trimester compared with first trimester trophoblast cells. Results were
extracted from the miRNA arrays (Fig. 1). The horizontal line defines the expression in first trimester trophoblast cells, values above and below this level display gene up- or down-
regulation, respectively.
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A comprehensive study on small RNAs in pregnancy described
the miRNA expression profiles of the human first trimester and
term placentae. Furthermore, in term placentae whole-villi and
terminal-villi have been analyzed separately [18]. We decided to
compare these profiles with those of isolated trophoblast cells in
the present study. Among the 20 highest expressed miRNAs in first
trimester trophoblast cells 5miRNAswerewithin the group (n¼ 28
miRNAs) of the highly clonedmiRNAs fromwhole placenta: miR-21,
miR-199a, miR-30b, miR-191, miR-24 and miR-30c. Similarly, the
comparison of term isolated trophoblast cells and placenta villi
revealed seven miRNAs highly expressed in both (miR-517a, miR-
200c, miR-30b, miR-24, miR-517c, miR-519a and miR-512-3p).
Eight out the 20 miRNAs with the lowest Ct in trophoblast cells
in our study belong to C19MC. This is concordant with a very recent
study which underlines that the C19MC miRNAs are the most
abundant in human term trophoblast [24]. However, it cannot be
assumed that exclusively trophoblast cells, but no other cell types
within the tissue, express these miRNAs. In our hands, more than
90% of cells were trophoblast cells, but for final clarification it will
be necessary to analyze the expression profiles of contaminating
cell types separately. The trophoblastic origin of most of the
detected miRNAs can also be supported by their detection in the
different analyzed trophoblastic cell lines.
For the study of the molecular mechanisms involved in the
regulation of trophoblast proliferation and invasion an increasing
variety of cell lines are used as models due to the limitations of
primary cultures. The investigated cell lines here include the most
accepted models: HTR-8/SVneo, JEG-3, AC1-M59 and ACH-3P.
However, it is still controversially discussed to which extend they
resemble trophoblast cells and how to extrapolate results from
these models for generation of hypotheses for the different physi-
ological trophoblast subtypes. On the one hand, HTR-8/SVneo cells
have the advantage of being benign first trimester trophoblast cells,
but vector transformation as used for their immortalization may
induce uncontrolled amplification and splicing of viral DNA
resulting in a heterogeneous genotype [25]. On the other hand,
choriocarcinoma cells are not virus-treated, but have, due to their
malignant origin, different functional characteristics and gene
expression patterns from physiological trophoblast cells [30].
Recent studies on several trophoblastic cell lines and isolated
primary trophoblast cells demonstrate that mRNAs signatures
allow differentiation between choriocarcinoma-derived cell lines,
immortalized trophoblast cell lines and primary trophoblast cells
[21,31]. Also several functional differences, mainly in regard to
invasiveness and proliferation, and in combination with different
expression patterns of mRNA and proteins including HLA mole-
cules, have been described between HTR-8/SVneo cells and
choriocarcinoma cells [21,32e34]. Similar to these observations, in
the current study, we demonstrate that miRNA profiles of the
choriocarcinoma-derived cell lines JEG-3, ACH-3P and AC1-M59
share large congruences with each other, but not with HTR-8/
SVneo. In comparison with primary first and third trimester
trophoblast cells by performing unsupervised hierarchical clus-
tering, miRNA profiles of choriocarcinoma-derived cell lines
resemble more the primary trophoblast cells than profiles from
HTR-8/SVneo do. These similarities depend mainly on the expres-
sion of the miRNA cluster C19MC.
Due to its placenta specificity, it can be expected that alterations
of C19MC may be involved in pregnancy pathologies by being their
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* * *
Fig. 3. Confirmation of array data by individual qRT-PCR. Relative expression of miRNAs belonging to either C19MC (miR-519e and miR-518a-5p), miR-371-3 cluster (miR-373) or
C14MC (miR-539 and miR-411) as well as further selected miRNAs which have been analyzed in previous studies [26] was analyzed in four cell lines and isolated first and third
trimester trophoblast cells. Data is presented as mean fold change (Log2RQ) compared to mean expression in first trimester isolated trophoblast cells  SE. The fold change has been
calculated using the delta-delta-Ct method using first trimester trophoblast cell results as calibrators and RNU44 and RNU48 as endogenous controls. *p < 0.05 (when compared
with isolated trophoblast cells; one-tailed Student’s t-test).
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brain, a distal CpG-rich region on chromosome 19 is hyper-
methylated, which inhibits the C19MC expression. This region can
be demethylated in several human cancers, which leads to
expression of the respective miRNAs [16]. It can be argued that
C19MC miRNA expression in choriocarcinoma cells derives from
their trophoblastic origin, their cancerous properties or from both,
which may explain the mostly higher C19MC expression than in
primary trophoblast cells. In contrast to C19MC, another placenta
(embryonic tissue and brain) specific miRNA cluster, C14MC [29], is
highly expressed in HTR-8/SVneo and in primary first and third
trimester trophoblast cells, but it is almost absent in the here
analyzed choriocarcinoma-derived cell lines. In a previous study,
several members of both clusters have been detected in cell-free
plasma of pregnant women [17]. The concentrations of members
of C19MC increased with the progress of pregnancy [17] and
decrease dramatically after delivery [18]. C19MC members can also
be detected in exosomes in serum of pregnant women [24]. Our
results go in line with these observations. We are providing
evidence that the C19MC and C14MC miRNAs are among the most
abundant expressed by trophoblast cells but also that their
expression correlates with the gestational age: C19MC increases
throughout pregnancy while C14MC decreases. The expression
levels of C19MC in the two hybrid cell lines ACH-3P and AC1-M59,
which were developed by fusion of JEG-3 with isolated trophoblast
cells from first and third trimester placentae, seems to reflect the
gestational age of the fused trophoblast cells, as an increase of miR-
371-3 cluster and a decrease of C14MC expression from ACH-3P to
AC1-M59 was detectable.
A further major difference between choriocarcinoma and HTR-
8/SVneo cells is, that JEG-3 cells and their hybrids express the
human embryonic stem cell specific miR-371-3 cluster, while HTR-
8/SVneo do not. This miRNA cluster was also observed in primary
trophoblast cells and its expression increases slightly in third
trimester. The miR-371-3 cluster is thought to be involved in stem
cell maintenance [35] and cell differentiation [36]. Therefore, it is
expectable that it also plays a functional role in the trophoblast
differentiation.
We further analyzed the expression of two pregnancy-associ-
ated miRNAs by qPCR: miR-21 and miR-141. As discussed above, in
another study, miR-21 was the highest cloned miRNA from human
placenta [18]. In concordance, we also found it highly expressed in
all tested cells (Ct < 23). Indeed, it showed the lowest Ct-value in
first trimester isolated trophoblast cells. MiR-21 is also strongly
secreted by human mesenchymal stem cells derived from embry-
onic stem cells [37], and its overexpression in a variety of cancer
types [38] which correlates with their elevated proliferation and
Table 3
Heatmapped list and chromosome localization of the 20 (out of 762) miRNAs with lowest Ct-values in isolated first or term trophoblast cells for a rough estimation of cell line
dependent distinct expression levels. Mean Ct-values of thesemiRNAs are listed for all analyzed cell types. Background colors: black: Ct-value< 20; dark gray: Ct-value 20e25;
light gray: Ct-value 25e30; white: Ct-value > 30. RNU48: Endogenous control.
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invasiveness [39,40]. Based on the high expression in trophoblast
cells, it may be argued that miR-21 is involved in enhanced
trophoblast proliferation and invasion during the initial steps of
implantation and placentation. Similarly to miR-21, miR-141 was
highly expressed in all tested cells and approximately 128fold
higher in first trimester trophoblast cells. Its downregulation
resulted in a decrease of trophoblast proliferation [26]. Both, miR-
21 and miR-141, can be found in significant amounts in the
maternal circulation. They are delivered in an exosome-mediated
manner [17,18]. Therefore, their expression level may be useful
for monitoring regular pregnancy progress, since it is to expect that
they mirror the status of the placenta.
Finally, the expression of two exemplary miRNAs associated
with cancer was measured. MiR-9 expression correlates with
tumor-grade and metastatic status in breast and cervical cancer
[39,41]. The expression of miR-9 in all trophoblastic cell lines was
similar and higher than in isolated trophoblast cells. This may be
a result of the transformation with SV40 in HTR-8/SVneo or reflect
their choriocarcinoma origin. On the other hand, low expression of
let-7g in the choriocarcinoma cells, but not in the HTR-8/SVneo,
goes in line with the observation that suggests let-7g as a tumor
suppressor. It has previously been reported that low expression of
let-7g is associated with unfavorable outcome in gastric cancer [42]
and that let-7g inhibits proliferation of hepatocellular carcinoma
[43]. Although the expression pattern of these two miRNA in
malignant and non-malignant trophoblastic cells corresponds to
that of other cell types and their malignant counterpart, the
observation cannot be generalized for other miRNA associated with
cancer.
However, the qPCR results of miR-9 and let-7g expression
confirm the observations of the array data. In general, the qPCR
data of the 9 individually analyzed miRNA supported widely the
array results, although a few quantitative differences appeared.
6. Conclusion
Our study provides a comprehensive encyclopedia of the
microRNA expression profile of four cell lines widely used as
models of trophoblast cells, and their comparison with primary
isolated trophoblast cells from first and third trimester. In regard to
the current international discussion about the nature of HTR-8/
SVneo cells, this study confirms their close relationship with
primary trophoblast cells, but it also exhibits large inequalities.
Simultaneously, it demonstrates that also choriocarcinoma cell
lines express trophoblast-specific miRNA patterns, but it displays
also numerous dissimilarities. Therefore, it may be concluded that
the use of a single cell line as a model for trophoblast cells carries
the risk of misleading to erroneous hypotheses, Results obtained
from such models require validation through the analysis of
primary cells.
The here presented encyclopedia may be useful for comparison
of trophoblastic cells with other cell types and tissues, for inter-
pretation of any experimental results from the analyzed cell lines,
for future analyses of function of major trophoblast-related miRNA
clusters, or for selection of novel miRNA targets for further
investigations.
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a  b  s  t  r a  c t
MicroRNAs  (miRNAs)  are  expressed in  the  placenta and  can be detected  in maternal  plasma.
An  increasing number  of studies  have  been  published on the  cellular  origin,  distribution
and  function  of miRNAs  in pregnancy.  Specific  miRNA  profiles  have  been described for
the  placenta,  maternal  plasma  and several pregnancy  disorders.  It  has been  observed  that
numerous miRNAs,  which  are  predominantly  or  exclusively  expressed  during  pregnancy,
are  clustered in chromosomal  regions,  may  be  controlled  by  the  same  promoters, may  have
similar seed  regions  and targets, and work  synergistically.  The three  most eminent  clusters
are the  chromosome 19 miRNA  cluster  (C19MC),  C14MC and  miR-371-3  cluster, which  is
also  localized  on chromosome  19.  MiRNA  members of these  clusters are not only detected
in  the  placenta,  but  also in other  compartments, e.g.  in serum  where  they  have  the  potential
to  become  novel  biomarkers of pregnancy disorders. Additionally,  some  members  are  also
expressed in a variety  of tumors.  Antagonism of selected  miRNAs  or  their  targets may
lead  to novel  strategies for the  development  of new  drug  classes  in  pregnancy disorders
or  other  diseases. This  review summarizes  current  knowledge  on the  pregnancy-related
miRNA  clusters  –  the  C19MC,  C14MC  and miR-371-3  cluster  – in regard to pregnancy and
also  other,  mostly pathological  circumstances.
© 2012 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
The study of gene regulation beyond the DNA tran-
scription has provided important novel interpretations of
genetic  research and has generated great interest in the
field  of human reproduction. Epigenetics is  defined as the
study  of changes in gene expression that are not caused by
changes  in the DNA sequence (Maccani and Marsit, 2009;
Wilkins-Haug, 2009). Four main mechanisms are consid-
ered  as epigenetic processes: DNA methylation, imprinting,
histone modification, and small RNA-mediated control,
specifically through microRNAs (miRNAs) (Maccani and
Marsit,  2009).
∗ Corresponding author. Tel.: +49 3641 933763; fax: +49 3641 933764.




MicroRNAs are single-stranded RNA molecules which
act as translational repressors by either degrading or
inhibiting translation of mRNA targets (reviewed by
Morales  Prieto and Markert, 2011). miRNAs control
numerous cellular processes including metabolism, cell
proliferation, apoptosis, and differentiation in almost all
cell  types (Seitz et al., 2004; Cheng et al., 2005; Bueno
et al., 2008; Chen et al., 2010). MiRNAs are known to be
involved in processes associated with establishment and
maintenance of pregnancy including preparation of the
endometrium for implantation (Pan and Chegini, 2008),
control of genes associated with inflammatory responses
(Chakrabarty et al., 2007), and regulation of immune
tolerance-associated genes, such as HLA-G (Veit and Chies,
2009).
During embryogenesis, critical periods are controlled
by  epigenetic modification of genes: gamete development,
preimplantation embryo development, and placentation
(Wilkins-Haug, 2009). Recent studies have demonstrated a
0165-0378/$ – see front matter ©  2012 Elsevier Ireland Ltd. All rights reserved.
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placenta-specific miRNA profile (Liang et al., 2007), which
seems  to be dominated by miRNAs expressed in tro-
phoblast cells (Donker et al., 2012; Morales-Prieto et al.,
2012).  This expression is, at least partly, reflected in the
maternal plasma (Chim et al., 2008; Luo et al., 2009) and
includes  the expression of numerous miRNAs localized
within three miRNA clusters: chromosome 14 miRNA clus-
ter  (C14MC), C19MC and the miR-371-3 cluster (Liang
et  al., 2007; Miura et al., 2010; Morales-Prieto et al.,
2012). Expression of miRNAs from these clusters changes
throughout pregnancy (Miura et al., 2010; Morales-Prieto
et al., 2012) and differs among placentas from patients
with preterm labor compared to  normal term pregnan-
cies (Mayor-Lynn et al., 2011). Remarkably, these clusters
are located within imprinted genes which are  known to
be  involved in human embryonic development and to play
important  roles in the regulation of cellular differentiation
and fate (Tsai et al., 2009).
In this review, we summarize the current informa-
tion about the expression of the pregnancy-related miRNA
clusters – C14MC, C19MC and miR-371-3 cluster – their
correlation with pregnancy disorders and their possible rel-
evance  as biomarkers for the detection and treatment of
pregnancy-associated diseases.
2. The chromosome 14 microRNA cluster (C14MC)
C14MC has also been referred to  as the Mirg cluster
(Bortolin-Cavaille et al., 2009), the miR-379/miR-410 clus-
ter  (Noguer-Dance et al., 2010) or the miR-379/miR-656
cluster (Glazov et al., 2008). It is  the largest described
miRNA cluster and comprises 52 miRNA genes located
within two closely neighboring segments spanning about
40  kb (Fig. 1) (Seitz et al., 2004; Gardiner et al., 2012;
Morales-Prieto et al., 2012). Located at the imprinted DLK-
DIO3  domain on the human 14q32 chromosomal interval
(mouse distal chromosome 12), C14MC is  exclusively
expressed from the maternally inherited chromosome and
is  regulated by methylation of a  distal Intergenic Germline-
derived Differentially Methylated Region (IG-DMR) (Fig. 1)
(Seitz  et al., 2004). The expression pattern of this clus-
ter  revealed a tissue-specific expression in mice: C14MC
is  mostly expressed in  developing embryonic (head and
trunk)  and placental tissues, and in adults, it is  restricted to
brain  (Seitz et al., 2004). Similarly, the analysis of healthy
human tissues revealed that some members of C14MC are
predominantly expressed in placenta or epithelial tissues
(Liang  et al., 2007).
The  origin of C14MC dates back to a  precursor sequence
which appeared approximately 100 million years ago in an
early  mammalian ancestor after the radiation of Metathe-
ria  (marsupial) or  Prototheria (monotreme) (Glazov et al.,
2008).  This sequence was amplified by tandem duplication
resulting in a ∼45 kb genomic region that encompasses the
C14MC  region (Hertel et al., 2006; Glazov et al., 2008). The
cluster  has been preserved without significant structural
changes and is uniquely found in  eutherian species (the
placental mammals) (Glazov et al., 2008; Bortolin-Cavaille
et al., 2009). This suggests that C14MC miRNAs may play
important biological roles in this animal lineage, including
the  control of neurogenesis, embryonic development,
transcriptional regulation, and RNA metabolism (Grun
et  al., 2005). Therefore, it has been suggested that evolution
of  the placental mammals was facilitated by this miRNA
cluster (Glazov et al., 2008).
3.  The chromosome 19 microRNA cluster (C19MC)
C19MC is one of the largest miRNA gene clusters
in human, maps to chromosome 19q13.41, and spans a
∼100  kb long region. C19MC miRNAs are primate-specific,
conserved in humans and comprise 46 miRNA genes (Fig. 2)
(Bentwich et al., 2005; Bortolin-Cavaille et al., 2009; Lin
et  al., 2010). The C19MC members share common seed
sequences and are supposed to be  originated from a  com-
mon  ancestor, which might be a  member of the miR-371-3
cluster (Zhang et al., 2008).
Similar  to C14MC, C19MC is located within imprinted
genes and is only expressed from the paternally inherited
chromosome. Its expression is controlled by methylation
at the upstream CpG rich promoter region at 17.6 kb of
C19MC (Noguer-Dance et al., 2010). Remarkably, C19MC
miRNA genes are enriched by dispersed Alu elements
approximately 10 times more than other regions, sug-
gesting a co-evolution of Alu sequences and miRNAs
(Zhang et al., 2008; Lehnert et al., 2009). The functions
of  these repeat elements and their cooperation with miR-
NAs  remain unclear. Nevertheless, some reports suggest
an  involvement of these sequences in  the regulation of the
genome structure and gene expression (Zhang et al., 2008;
Lehnert  et al., 2009). Moreover, the expression of miRNAs
seems to be partly regulated by Alu elements (Gu et al.,
2009;  Lehnert et al., 2009).
The  expression of C19MC is mainly restricted to the
reproductive system and placenta (Bentwich et al., 2005;
Liang  et al., 2007; Lin et al., 2010), although expression
of  miR-498 has been reported in fetal brain (20 weeks)
(Flor  and Bullerdiek, 2012), and some C19MC members are
highly  expressed in  human embryonic stem cells (ESCs)
(Bar  et al., 2008; Ren et al., 2009). In human and chim-
panzee ESCs, the number of miRNA genes which map  to the
chromosome 19 is  strongly increased (Cao et al., 2008). Fur-
thermore,  no  homologues of this miRNA cluster have been
found  in rat, mouse or dog which emphasizes its primate-
specificity (Zhang et al., 2008). Based on these observations,
it has been hypothesized that C19MC may  be related with
human  primate evolution and important for embryo devel-
opment  (Tsai et al., 2009).
4.  The miR-371-3 cluster
The miR-371-3 cluster consists mainly of 3 miRNAs
sharing the same seed sequence “AAG UGC”: hsa-miR-
371a-3p, hsa-miR-372 and hsa-miR-373-3p. Two  miRNAs
synthesized from the opposite site of the pre-microRNA
(hsa-miR-371-5p and hsa-miR-373-5p), as well as hsa-
miR-371b-3p complete the cluster (Griffiths-Jones et al.,
2006;  Persson et al., 2011). The miR-371-3 cluster in
humans is part of a  superfamily of miRNAs sharing the same
seed  sequence, which also includes the mouse homologue
cluster miR-290-295 (Houbaviy et al., 2003).
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Fig. 1. Schematic representation and genomic organization of chromosome 14 and 19 containing miRNA clusters. (A) Chromosome 14  miRNA cluster
(C14MC)  in the imprinted DLK-DIO3 domain on  the human 14q32 chromosomal interval. Highlighted miRNAs are relevant in pregnancy (adapted after
Cairo  et al., 2010). (B) C19MC (Hg19: 54  169 933–54 265 683) and miR-371-3 cluster mapping at chromosome 19q13.42 (modified from Noguer-Dance
et  al., 2010).
Fig. 2. Heat mapped expression of pregnancy-related microRNA clusters in trophoblast cells. Data is  presented as mean of dCt of all miRNAs in each cluster.
High  expression is represented by dark blue (adapted after Morales-Prieto et  al.,  2012).
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The miR-371-3 cluster is  located on chromosome 19
within  a 1050 bp region adjacent to the C19MC cluster
(Fig. 2) (Suh et al., 2004). Similar to C14MC and C19MC,
this cluster is conserved in mammals only (Houbaviy et al.,
2003)  and is predominantly expressed in  the placenta
(Bentwich et al., 2005). Interestingly, the members of the
miR-371-3 cluster are  highly expressed in human ESCs
(Laurent et al., 2008) and their levels decrease during devel-
opment (Suh et al., 2004), possibly marking a  “naïve” state
of  ESCs with the potential to enhance reprogramming of
fibroblasts  to induced pluripotent stem cells (Wilson et al.,
2009;  Kim et al., 2011; Subramanyam et al., 2011). Embry-
onic  stem cell-specific cell cycle regulating (ESCC-)miRNAs
such as the murine miR-290 cluster or the miR-371-3 clus-
ter  are essential for cell cycle maintenance (Wang et al.,
2008;  Qi et al., 2009) and for regulation of proliferation and
apoptosis (Voorhoeve et al., 2006; Cho et al., 2009).
5.  Circulating placenta-derived microRNA as novel
biomarkers
MicroRNA profiling of human placenta tissues revealed
high  expression of the clusters C19MC, C14MC and miR-
371-3.  Interestingly, their expression changes with the
gestational age and even differences between whole and
terminal  villi can be observed (Luo et al., 2009). Recent
reports have demonstrated that the placenta miRNome
comprises mostly miRNAs belonging to the C14MC and
C19MC  in the first and third trimester, respectively (Liang
et  al., 2007; Morales-Prieto et al., 2012). Further, in situ
hybridization of some C19MC members revealed that the
main  source of these miRNAs is  the trophoblast layer with
dominant signals in the syncytiotrophoblast (Zhang et al.,
2008;  Luo et al., 2009).
The  study of the trophoblast cell miRNome revealed that
C14MC  members are among the highest miRNAs expressed
in  primary first trimester trophoblast cells and also in
the  immortalized cell line HTR-8/SVneo (Morales-Prieto
et al., 2012). In contrast, miRNA expression of isolated third
trimester trophoblast cells was more similar to  that of
choriocarcinoma cell lines (JEG-3 and derivates) with a  pre-
dominance of C19MC and the miR-371-3 cluster (Donker
et  al., 2012; Morales-Prieto et al., 2012). Similar to the
observations in maternal plasma, levels of C14MC and
C19MC change throughout pregnancy. C14MC is highly
expressed by first trimester trophoblast cells but decreases
in  third trimester. Conversely, C19MC is  low expressed
during first trimester but highly expressed at the end of
pregnancy  (Morales Prieto and Markert, 2011) (Fig. 2).
Nevertheless, the expression of these clusters may  not
be  exclusive of trophoblast cells. A recent report demon-
strated expression of C19MC members in mesenchymal
stem cells originated from the villous mesenchymal core,
which  was free of trophoblast cells (Flor et al., 2012).
Recently, it has been demonstrated that trophoblast and
stromal  cells of the villi release exosomes into the maternal
circulation, which may  contain miRNAs belonging to the
C19MC  (Luo et al., 2009). One of the most interesting fea-
tures  of the circulating miRNAs is their high stability which
enables  them to resist enzymatic degradation, freeze-thaw
cycles and extreme pH conditions (Mitchell et al., 2008;
Zhao et al., 2012). Due to these characteristics miRNAs
have been proposed as potential blood-based biomarkers
for  the detection of tumors (Cortez and Calin, 2009). Sim-
ilarly,  circulating miRNA may  serve as biomarkers for the
detection  of pregnancy-associated diseases (Donker et al.,
2012;  Hromadnikova et al., 2012).
Expression of miRNAs in  pregnant women  differs
from that of non-pregnant women and thus, pregnancy-
related miRNAs may  become potential markers for the
establishment of pregnancy (Reid et al., 2010). Some
pregnancy-associated miRNAs, such as miR-526a and miR-
527  are 600-fold higher in serum of third trimester
pregnant women  than in non-pregnant women and allow,
as  also miR-520d-5p, discrimination between both groups
(Gilad et al., 2008). After termination of pregnancy, plasma
levels  of pregnancy-associated miRNAs belonging to both
C14MC  and C19MC decrease significantly, which under-
lines their placental origin (Miura et al., 2010; Kotlabova
et al., 2011). Expression of C19MC has been investigated
in order to identify miRNAs with diagnostic potential.
The findings revealed high expression of these miRNAs in
placenta tissue, trophoblastic cells and maternal plasma
(Table  1).
The  abundant expression of pregnancy-related miRNA
clusters in normal placentas also suggests that their alter-
ation  may  be related with pregnancy-associated diseases
such  as preeclampsia or growth retardation. Only few
studies have been published in  this field and there is
little  overlap among the data on C19MC and C14MC
members. For instance, miR-154* (in C14MC) was  found
initially up-regulated in  placenta tissue of patients with
preeclampsia associated with small-for-gestational-age
(Pineles et al., 2007), but a  second study found it down-
regulated in  severe preeclamptic placentas (Zhu et al.,
2009). Besides miR-154*, other C14MC species were
found  down-regulated in preeclamptic placentas: miR-
1247  (Enquobahrie et al., 2011), miR-411 and -377 (Zhu
et  al., 2009). In contrast, some members of the C19MC
were found up-regulated: miR-517*, -518b and -519* (Zhu
et  al., 2009), and miR-520a-3p, -518f, -517c, -518c, -525-
5p,  -526b and -519e (Ishibashi et al., 2012). In  addition,
another comprehensive analysis of 820 miRNAs showed
no  differences in their expression among normal pla-
centas and those from patients with preeclampsia, but
reported changes in placentas of preterm labor when
compared with the normal counterparts: Overexpression
of  members of C19MC (miR-517a, -518b, -512-3p and -
526b)  and C14MC (miR-431, -539 and -495) (Mayor-Lynn
et al., 2011). Remarkably, none of the above mentioned
miRNAs was simultaneously found in  two different stud-
ies.  In  fact, among the publications summarized in  this
review, only miR-210 was  found commonly up-regulated
in all studies suggesting its potential as biomarker for
preeclampsia. Further analysis revealed that miR-210 but
also  miR-518c target hydroxysteroid (17-) dehydroge-
nase 1 (HSD17B1), a steroidogenetic enzyme which is
decreased in  preeclamptic placentas and has been con-
sidered a  potential prognostic factor for preeclampsia
(Ishibashi et al., 2012).
Nonetheless,  the use of miRNA species as biomarkers for
preeclampsia is still controversial. A  recent study reported
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Table 1
Expression of C19MC miRNAs in placenta tissue, isolated trophoblast cells from first/third trimester placentas and maternal plasma.
miRNA Expression References miRNA Expression References
miR-498 P, T, MP  Bentwich et al. (2005), Liang et al.
(2007), Bortolin-Cavaille et  al.
(2009), Miura et al. (2010), Donker
et al. (2012)
miR-519b-3p F, T Donker et  al. (2012),
Morales-Prieto et al. (2012)
miR-512-1 P Bortolin-Cavaille et al. (2009) miR-519c P, F Bentwich et  al. (2005),
Bortolin-Cavaille et al. (2009),
Morales-Prieto  et al. (2012)
miR-512-2 P Bortolin-Cavaille et al. (2009) miR-519c-3p F, T Donker et  al. (2012),
Morales-Prieto et al. (2012)
miR-512-3p F, T,  MP,  Gilad et al. (2008), Luo et al. (2009),
Donker et al. (2012),
Morales-Prieto  et  al. (2012)
miR-519d P, F, T, MP Bentwich et  al. (2005), Gilad
et al. (2008), Bortolin-Cavaille
et  al. (2009), Miura et  al.
(2010),  Kotlabova et al. (2011),
Donker  et  al. (2012),
Morales-Prieto et al. (2012)
miR-512-5p F, T,  MP  Kotlabova et  al. (2011), Donker
et al. (2012), Morales-Prieto et al.
(2012)
miR-519e P, F, T Bentwich et  al. (2005), Liang
et al. (2007), Bortolin-Cavaille
et  al. (2009), Morales-Prieto
et  al. (2012)
miR-515-1 P Bortolin-Cavaille et al. (2009) miR-519e# F, T, MP Gilad et al. (2008),
Morales-Prieto et al. (2012)
miR-515-2 P Bortolin-Cavaille et al. (2009) miR-520a P  Bentwich et  al. (2005), Liang
et al. (2007), Bortolin-Cavaille
et  al. (2009)
miR-515-3p P, F, T, MP Bentwich et al. (2005), Gilad et al.
(2008), Miura et al. (2010),
Kotlabova  et  al. (2011), Donker
et al. (2012), Morales-Prieto et al.
(2012)
miR-520a* MP  Kotlabova et al. (2011)
miR-515-5p  P, F, T, MP,  Liang et  al. (2007), Morales-Prieto
et  al. (2012)
miR-520a-3p F, T Morales-Prieto et al. (2012)
miR-516-1 P Liang et  al. (2007),
Bortolin-Cavaille et al. (2009)
miR-520a-5p F, T, MP Gilad et al. (2008), Donker et al.
(2012), Morales-Prieto et al.
(2012)
miR-516-2 P Liang et  al. (2007) miR-520b P, F, T Bentwich et  al. (2005), Liang
et al. (2007), Bortolin-Cavaille
et  al. (2009), Morales-Prieto
et  al. (2012)
miR-516-3 P Liang  et  al. (2007),
Bortolin-Cavaille et al. (2009)
miR-520c P Bentwich et  al. (2005), Liang
et al. (2007), Bortolin-Cavaille
et  al. (2009)
miR-516-4 P Bentwich et al. (2005),
Morales-Prieto  et  al. (2012)
miR-520c-3p F, T Donker et  al. (2012),
Morales-Prieto et al. (2012)
miR-516-3p P, F, T Bentwich et al. (2005), Kotlabova
et al. (2011), Morales-Prieto et al.
(2012)
miR-520d P  Bentwich et  al. (2005),
Bortolin-Cavaille et al. (2009)
miR-516-5p P, MP  Luo et al. (2009), Morales-Prieto
et  al. (2012)
miR-520d-3p F, T Morales-Prieto et al. (2012)
miR-516a-5p F, T Luo et al. (2009), Morales-Prieto
et  al. (2012)
miR-520d-5p F, T, MP Gilad et al. (2008), Augello
et  al. (2012), Morales-Prieto
et  al. (2012)
miR-516b F, T Liang et  al. (2007), Morales-Prieto
et  al. (2012)
miR-520e P, F, T Bentwich et  al. (2005), Liang
et al. (2007), Bortolin-Cavaille
et  al. (2009), Morales-Prieto
et  al. (2012)
miR-516b2-3 P Bentwich et al. (2005), Gilad et al.
(2008), Miura et al. (2010),
Kotlabova  et  al. (2011), Donker
et al. (2012), Morales-Prieto et al.
(2012)
miR-520f P, F, T Bentwich et  al. (2005), Liang
et al. (2007), Bortolin-Cavaille
et  al. (2009), Morales-Prieto
et  al. (2012)
miR-517# F, T,  MP  Gilad et  al.  (2008), Kotlabova et al.
(2011), Morales-Prieto et  al. (2012)
miR-520g P, F, T Bentwich et  al. (2005), Donker
et al. (2012), Morales-Prieto
et  al. (2012)
miR-517a P, F, T, MP Bentwich et al. (2005), Liang et al.
(2007), Bortolin-Cavaille et  al.
(2009), Luo et al. (2009), Miura
et al. (2010), Donker et al. (2012),
Morales-Prieto et  al. (2012)
miR-520h P, F, T, MP Bentwich et  al. (2005),
Kotlabova et al. (2011), Donker
et al. (2012), Morales-Prieto
et  al. (2012)
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miRNA Expression References miRNA Expression References
miR-517b P, F, T,  Bentwich et al. (2005), Liang et al.
(2007), Bortolin-Cavaille et al.
(2009), Luo et al. (2009), Donker
et al. (2012)
miR-521 P, F, T, MP Bentwich et al. (2005), Gilad
et al. (2008), Donker et al.
(2012), Morales-Prieto et al.
(2012)
miR-517c P, F, T,  MP Bentwich et al. (2005), Liang et al.
(2007), Bortolin-Cavaille et al.
(2009), Luo et al. (2009), Miura
et al. (2010), Donker et al. (2012),
Morales-Prieto et  al.  (2012)
miR-521-1 P Liang  et al. (2007)
miR-517c* MP Miura et al. (2010) miR-521-2 P  Liang et al. (2007),
Bortolin-Cavaille et al. (2009)
miR-518a P  Bentwich et al. (2005), Luo et  al.
(2009)
miR-522 P, F, T Bentwich et al. (2005),
Bortolin-Cavaille et al. (2009),
Donker  et al. (2012),
Morales-Prieto et al. (2012)
miR-518a-1 P Liang et al. (2007),
Bortolin-Cavaille et  al. (2009)
miR-523 P, F, T, MP Bentwich et al. (2005), Liang
et al. (2007), Gilad et al. (2008),
Bortolin-Cavaille  et al. (2009),
Morales-Prieto  et al. (2012)
miR-518a-3p P, F, T,  MP  Liang et al. (2007), Gilad et al.
(2008), Donker et al. (2012),
Morales-Prieto  et  al.  (2012)
miR-524 P, F, T, MP Bentwich et al. (2005), Liang
et al. (2007), Gilad et al. (2008),
Bortolin-Cavaille  et al. (2009),
Morales-Prieto  et al. (2012)
miR-518a-5p F, T Morales-Prieto et  al.  (2012) miR-524* MP Gilad et al. (2008)
miR-518b  P, F, T,  MP  Bentwich et al. (2005),
Bortolin-Cavaille  et  al. (2009), Luo
et al. (2009), Miura et al. (2010),
Kotlabova et al. (2011), Donker
et al. (2012), Morales-Prieto et  al.
(2012)
miR-524-3p T Donker et al. (2012)
miR-518c  P, F, T,  MP  Bentwich et al. (2005), Liang et al.
(2007), Bortolin-Cavaille et al.
(2009), Miura et al. (2010), Donker
et al. (2012), Morales-Prieto et  al.
(2012)
miR-524-5p F, T, MP Kotlabova et al. (2011),
Morales-Prieto et al. (2012)
miR-518c# F, T Morales-Prieto et  al.  (2012) miR-525 P  Bentwich et al. (2005), Gilad
et al. (2008), Bortolin-Cavaille
et  al. (2009), Kotlabova et al.
(2011)
miR-518d P, MP Bentwich et al. (2005), Liang et al.
(2007), Gilad et al. (2008),
Bortolin-Cavaille  et  al. (2009)
miR-525-3p F, T, MP Miura et al. (2010),
Morales-Prieto et al. (2012)
miR-518d-3p F, T Morales-Prieto et  al.  (2012) miR-525-5p F, T, MP Kotlabova et al. (2011), Donker
et al. (2012), Morales-Prieto
et  al. (2012)
miR-518d-5p F, T Morales-Prieto et  al.  (2012) miR-526a P, MP Gilad et al. (2008), Miura et al.
(2010), Kotlabova et al. (2011)
miR-518e P, F, T,  MP  Gilad et al. (2008),
Bortolin-Cavaille et  al. (2009), Luo
et al. (2009), Donker et al. (2012),
Morales-Prieto et  al.  (2012)
miR-526a-1 P  Liang et al. (2007),
Bortolin-Cavaille et al. (2009)
miR-518e# F, T Morales-Prieto et  al.  (2012) miR-526a-2 P  Liang et al. (2007)
miR-518f  P, F, T Bortolin-Cavaille et  al. (2009), Luo
et al. (2009), Donker et al. (2012),
Morales-Prieto et  al.  (2012)
miR-526b P, F, T, MP Bentwich et al. (2005), Liang
et al. (2007), Miura et al.
(2010),  Kotlabova et al. (2011),
Donker  et al. (2012),
Morales-Prieto et al. (2012)
miR-518f# F, T Morales-Prieto et  al.  (2012) miR-526c P, MP Bentwich et al. (2005), Liang
et al. (2007), Gilad et al. (2008)
miR-519a P, F, T,  MP  Bentwich et al. (2005), Luo et  al.
(2009), Miura et al. (2010),
Kotlabova  et al. (2011),
Morales-Prieto et  al.  (2012)
miR-527 P, MP Bentwich et al. (2005), Liang
et al. (2007), Gilad et al. (2008)
miR-519a* MP Kotlabova et al. (2011) miR-1283 F, T Morales-Prieto et al. (2012)
miR-519a-1 P  Bortolin-Cavaille et  al. (2009) miR-1283-1 P  Liang et al. (2007)
miR-519a-2  P  Bortolin-Cavaille et  al. (2009) miR-1283-2 P  Liang et al. (2007)
miR-519b  P  Bentwich et al. (2005), Liang et al.
(2007), Bortolin-Cavaille et al.
(2009), Morales-Prieto et al. (2012)
miR-1323 P, T Bortolin-Cavaille et al. (2009),
Donker  et al. (2012)
P, placenta tissues; F, trophoblast cells isolated from first trimester placentas; T, trophoblast cells isolated from normal term placentas; MP,  maternal
plasma.
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Table 2
C14MC members with published target or associated with pregnancy pathologies.
miRNA Target Expression Associated pathologies References
hsa-miR-136 Preterm labor
Gliomas





Chim et al. (2008), Zhu et  al. (2009),
Lavon et  al. (2010), Miura et al. (2010),
Enquobahrie et  al.  (2011), Gattolliat
et al. (2011), Mouillet et al. (2011)
hsa-miR-154* P, T, MP ↑↓PE
Gliomas
Neuroblastoma
Pineles et  al. (2007), Chim et al. (2008),
Zhu et al. (2009), Lavon et al. (2010),
Miura et al. (2010), Gattolliat et al.
(2011), Mouillet et  al. (2011)
hsa-miR-299 OPN  MP Neuroblastoma
Gliomas
Chim et al. (2008), Lavon et al. (2010),
Gattolliat et al. (2011)





Chim et al. (2008), Lavon et al. (2010),
Gattolliat et al. (2011)
hsa-miR-329  PDGFA, E2FI Neuroblastoma Lavon et  al. (2010), Miura et al. (2010),
Gattolliat et al. (2011), Genovesi et al.
(2011), Zhao et  al. (2012)
hsa-miR-342  EVL, PDGFRA MP ↑sPE
Multiple myeloma
Haller et al. (2010), Wu et al. (2012)
hsa-miR-369 Preterm labor
Gliomas
Haller et al. (2010), Gattolliat et al.
(2011)




Lavon  et  al. (2010), Mouillet et al.
(2011)
hsa-miR-376 CDKNIA Medulloblastoma Haller et al. (2010), Lavon et al. (2010),
Mouillet et al. (2011)
hsa-miR-377  PUM2, SOD1, SOD2,








Zhu et  al. (2009), Gattolliat et al. (2011)
hsa-miR-410 CDK1 Neuroblastoma Haller et al. (2010), Gattolliat et al.
(2011), Genovesi et al. (2011)
hsa-miR-411  PPP1CC, USP42,
PCDH10, RANBP9
P,  F, MP  ↓sPE Gattolliat et al. (2011)
hsa-miR-433  P, F, T,  MP  Zhu et al. (2009), Miura et  al.  (2010),
Enquobahrie et  al.  (2011)
hsa-miR-485  NF-KB Neuroblastoma Miura et al. (2010)
hsa-miR-487  P, F, MP  Neuroblastoma Gattolliat et al. (2011)
hsa-miR-494 Preterm labor
Medulloblastoma
Miura et al. (2010), Gattolliat et al.
(2011), Genovesi et al. (2011)




Genovesi et  al. (2011), Mouillet et al.
(2011)
hsa-miR-654 CDKN1A Neuroblastoma Gattolliat et al. (2011), Genovesi et al.
(2011)
hsa-miR-1247 P ↓PE Gattolliat et al. (2011)
P, predominant expression in placenta tissues; F, first trimester; T, third trimester; sPE, severe pre-eclampsia; PE, pre-eclampsia; MP,  maternal plasma.
no differences in the plasma levels of individual miRNAs
in  women with preeclampsia (Hromadnikova et al., 2012),
while  other authors reported deregulation up to 22 miR-
NAs  (Yang et al., 2011; Wu  et al., 2012). Application of
next  generation solid sequencing uncovered 15 miRNAs
up-regulated and 7 down-regulated in plasma of women
with  preeclampsia. Among them, eight miRNAs belong-
ing  to C19MC were found up-regulated (miR-521, -520h,
-517c,  -519d, -517d, -542-3p, -518e and -519a) (Yang et al.,
2011).  A different study showed 13 miRNAs up-regulated
and 2 down-regulated in plasma of patients with severe
preeclampsia, out of which miR-342-3p (C14MC member)
was  found up-regulated (Wu  et al., 2012). Again, no simi-
larities were observed between the data in both studies.
Despite the fact that no individual miRNA has been
confirmed yet as a  biomarker for preeclampsia, signifi-
cant elevation of extracellular miRNAs was  found between
the  12th and the 16th week of pregnancy in maternal
circulation of women  who  later develop preeclampsia
(Hromadnikova et al., 2012). Likewise, analysis of plasma
from  women with pregnancies complicated with term FGR
revealed  no differences in the expression of individual
miRNAs, but when considered as a  group, there was a
significant increase in  total miRNA levels (Mouillet et al.,
2010).
Other pregnancy pathologies are associated with
changes in  the expression of C19MC and C14MC mem-
bers.  Decreased miR-518b, miR-519c and miR-520h
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Table  3
mRNA targets of the human miR-371-3 cluster.
miR  Target Function of target Tissue/cell line References
hsa-miR-372
LATS2 Tumor suppressor AGS, MCF-7, Tera-1 Enquobahrie et  al.  (2011)
TXNIP Redox regulator, tumor suppressor Caco-2, HCT-116,
SW-620
Voorhoeve  et al. (2006), Cho
et al. (2009)




Ragusa  et  al. (2012)
P21 G1/S  transition HeLa, Dicer
knockdown hESCs
Xu et  al.  (2009), Subramanyam
et  al. (2011), Zhou et al. (2011)
hsa-miR-372
hsa-miR-373
NFIB  Oncogene HepG2 cells Qi et al. (2009)
ZEB1  Binding at E-boxes PC3 Guo et al. (2011)
BTG1  Anti-proliferative MCF-7 Mazda et al. (2011)
LEFTY1  TGFbeta signaling MCF-7 Zhou et al. (2011)
DKK1  Blocks Wnt  signaling, tumor suppressor MCF-7, HCT 115
(CRC-cells)
Zhou  et al. (2011)
RECK Tumor  suppressor, essential for
mammalian development
Zhou et al. (2011)
hsa-miR-373
RAD23B  ↓ Nucleotide excision repair mechanism HeLa, MCF-7,
HIF-1, MEF
Loayza-Puch et al. (2010)
LATS2  Tumor suppressor Huh6, MCF-7,
Tera-1
Crosby  et  al. (2009)













Huang  et al. (2008)
CSDC2  – promotor
sites
Cold  shock domain-containing protein C2 PSC-3,  HCT-116
(CRC-cells)
Place  et al. (2008)
has-miR-371-3 Myc  Transcription factor Place et al. (2008)
concentrations were detected in  serum of women  with
preterm labor when compared with normal pregnancies
at term (Montenegro et al., 2009). Expression of miR-517a,
miR-517b, miR-518b and miR-519a is  significantly reduced
in  complete hydatidiform mole tissues (Na  et al., 2012).
An  increase in miR-323-3p has been proposed as a novel
marker for the early detection of ectopic pregnancy (Zhao
et  al., 2012). Thus far, no member of the miR-371-3 cluster
has  been found to discriminate pregnancy disorders (Chim
et  al., 2008; Gilad et al., 2008; Luo et al., 2009; Miura et al.,
2010;  Kotlabova et al., 2011). This increasing spectrum
of studies and observations highlights the potential of
microRNAs as a clinical tool for the diagnosis, treatment
and prognosis of a variety of pregnancy disorders.
6. MicroRNA clusters, clinical applications and
cancer
Human miRNA genes may  function as oncogenes and/or
tumor suppressors because they are frequently located at
fragile  genomic regions involved in  cancer (Calin et al.,
2004).  Pregnancy-related miRNAs are not only expressed in
pregnancy  associated diseases, but their deregulation can
also  correlate with the development of several tumors. A
recent  study in neuroblastoma revealed that most of the
recurrent large-scale chromosomal imbalances, including
loss  of C14q, had impact on the miRNA expression (Bray
et  al., 2009). Increasing number of studies demonstrate that
the  chromosome region of C14MC is frequently deleted
or  genetically altered in hematopoietic and solid tumors,
suggesting C14MC as the largest tumor suppressor cluster
(Haller  et al., 2010; Lavon et al., 2010).
The expression profiles of 180 miRNAs in  glial tumors,
embryonic stem cells, neural precursor cells and nor-
mal  adult brain tissues revealed that gliomas have
a neural precursor cell-like miRNA signature. C14MC
was  down-regulated in all tested gliomas, and in  addi-
tion, low expression of C14MC indicates higher risk of
tumor  progression (Haller et al., 2010; Lavon et al.,
2010). Similarly, the study of 734 human miRNAs and
their potential correlation with gastrointestinal stromal
tumors identified 44 miRNAs, located in  the chromoso-
mal  region 14q32.31, which were down-regulated in such
tumors (Haller et al., 2010). The relationship between
the C14MC expression and the risk of tumor progression
has suggested the potential of these miRNAs for clini-
cal  application, such as miR-487b and miR-410 which
may  serve as markers for neuroblastoma diagnosis and
prognosis (Gattolliat et al., 2011). Further associations
of  C14MC miRNAs and human diseases are  reviewed in
Table  2.
In  contrast to C14MC, upregulation of C19MC miRNAs
is related with tumor development (Flor and Bullerdiek,
2012). Overexpression of C19MC members has been
reported in  several cancers: Increase of miR-519d levels
in  hepatocellular carcinoma cells which correlates with
hypomethylation of C19MC can activate cell prolifera-
tion and invasion, and impairs apoptosis after doxorubicin
treatment (Fornari et al., 2012). Several survival genes
are  directly targeted by miR-519 in  hepatocellular car-
cinoma cells including CDKN1A/p21, PTEN, AKT3 and
TIMP2 (Fornari et al., 2012). Overexpression of miR-
519  induced cellular senescence through HuR inhibition
(Marasa et al., 2010). Additionally, the C19MC members:
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miR-515-5p, miR-518a-3p, miR-520f and miR-525-3p are
overexpressed in hepatocellular carcinoma cells. Their
serum  levels might become useful for improvement of
diagnosis in early hepatocellular carcinoma and liver dys-
plasia  (Augello et al., 2012).
Deregulation  of C19MC is also present in several
cancers within the reproductive system. In breast can-
cer  the C19MC member miR-520c-3p promotes tumor
invasion and metastasis (Huang et al., 2008). Similarly,
three miRNAs (miR-516a-5p, miR-518c* and miR-519a)
are highly expressed in endometrial adenocarcinoma
whereas miR-518b is  down-regulated in  cervical carci-
noma  (Gilabert-Estelles et al., 2012).
MicroRNA profiling has revealed that miRNAs of the
miR-371-3 cluster are, at least partially, up-regulated in
several  cancers, such as in  testicular germ cell tumors
(Voorhoeve et al., 2006; Palmer et al., 2010), gliomas
(Lavon et al., 2010), hepatoblastoma (Cairo et al., 2010),
breast  cancer (Huang et al., 2008), thyroid adenomas (Rippe
et  al., 2010) and colorectal tumors (Bandres et al., 2006).
Several tumor suppressors and cell cycle regulators are
targeted  by members of the miR-371-3 cluster, such as
LATS2  (Voorhoeve et al., 2006; Cho et al., 2009; Cairo et al.,
2010),  TGFBRII (Subramanyam et al., 2011; Zhou et al.,
2011),  p21 (Qi et al., 2009), BTG1 and LEFTY1 (Zhou  et al.,
2011),  as well as DKK1 as part of a  suggested feedback-loop
involving Wnt/-catenin (Zhou et al., 2011). In hypoxic
cells, miR-373 increases genomic instability by  targeting
RAD23B (Crosby et al., 2009) and miR-372 and miR-373
are  activated by TWIST and suppress RECK, another potent
tumor  suppressor (Loayza-Puch et al., 2010). MiR-373 stim-
ulates  tumor invasion and metastatic potential in  vitro
and  in vivo by decreasing the expression of CD44 (Huang
et  al., 2008). E-cadherin expression can not only be influ-
enced  by miR-372 and miR-373 via targeting ZEB1 (Mazda
et  al., 2011), but also by  miR-373 binding to comple-
mentary sequences in its promoter region (Place et al.,
2008).  Apart from cancer pathogenesis, miR-371-3 stimu-
lates  hepatitis B virus production in  a hepatocellular tumor
cell  line, most likely via targeting nuclear factor I/B (Guo
et  al., 2011). Targets of the miR-371-3 cluster, their func-
tion  and association with human diseases are reviewed in
Table  3.
7.  Conclusion and perspectives
Human pregnancy is accompanied by the expression
of a large number of pregnancy-related miRNAs. Many of
these  miRNAs are physiologically expressed almost exclu-
sively  in the placenta or in a few fetal tissues. In humans,
they are mostly clustered on  chromosome 14 (C14MC) and
chromosome 19 (C19MC and miR-371-3 cluster). Numer-
ous  members of these clusters can be detected in maternal
serum and seem to reflect the state of the placenta and
might indicate pregnancy disorders. Therefore, there is
a  strong potential for these miRNAs to  become novel
biomarkers in pregnancy. Targeting or mimicking these
miRNAs  may  lead to novel therapeutic concepts. Several
pregnancy-related miRNAs have been also detected in cor-
relation  with malignant tumors of different origin, and in
these  situations, may  have a  similar potential for becoming
future  biomarkers.
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a b s t r a c t
MicroRNAs (miRNAs) regulate the expression of a large number of genes in plants and animals. Placental
miRNAs appeared late in evolution and can be found only in mammals. Nevertheless, these miRNAs are
constantly under evolutionary pressure. As a consequence, miRNA sequences and their mRNA targets
may differ between species, and some miRNAs can only be found in humans. Their expression can be
tissue- or cell-specific and can vary time-dependently. Human placenta tissue exhibits a specific miRNA
expression pattern that dynamically changes during pregnancy and is reflected in the maternal plasma.
Some placental miRNAs are involved in or associated with major pregnancy disorders, such as pre-
eclampsia, intrauterine growth restriction or preterm delivery and, therefore, have a strong potential for
usage as sensitive and specific biomarkers. In this review we summarize current knowledge on the origin
of placental miRNAs, their expression in humans with special regard to trophoblast cells, interspecies
differences, and their future as biomarkers. It can be concluded that animal models for human repro-
duction have a different panel of miRNAs and targets, and can only partly reflect or predict the situation
in humans.
 2013 Published by IFPA and Elsevier Ltd.
1. Introduction
Placentas from eutherian mammals have developed a wide
phylogenetic diversity. They can be roughly categorized in epi-
theliochorial, endotheliochorial and haemochorial placentas [1].
Evenwithin these groups, however, somemajor differences remain.
For instance, human and mouse placentas belong to the hae-
mochorial type but the human placenta features a range of prop-
erties not present in mice with regard to cell biology [2], endocrine
system [3], immune system [4] and placental transport [5].
Understanding such interspecies differences is of crucial
importance for the elucidation of evolutionary processes. Addi-
tionally, there is an enormous practical relevance because animals
serve as models for the investigation of pregnancy and its disorders
and for toxicological tests, often with limited relevance for humans
[6]. Interspecies differences are mostly caused by gene evolutionary
mechanisms which include duplication, divergence and reassort-
ment of gene segments [7]. Additionally, gene regulatory mecha-
nisms play a significant role in species divergence. These
mechanisms comprise, among others, differences in promoter
sequences [8], species-specific transcriptional regulators [9],
epigenetic mechanisms such as histone modification [10], DNA
methylation [11], and microRNA (miRNA) expression [12].
In recent years, the impact of these regulators has attracted
attention. MiRNAs are small, single-stranded molecules of
approximately 20e24 nucleotides that are capable of binding to
messenger RNAs leading to downregulation of gene expression
[13]. Remarkably, human placenta exhibits a specific miRNA
expression pattern that dynamically changes during pregnancy
[14,15] and is reflected in the maternal plasma [16]. Some of these
miRNAs are dysregulated in pregnancy disorders like preeclampsia
and intrauterine growth restriction (IUGR), and are potential bio-
markers for these pathologies [17e19].
In this review we summarize current knowledge on the origin
and expression of human placenta miRNAs, their interspecies dif-
ferences, and their future as potential biomarkers.
2. Origin and evolution of placenta miRNAs
Creation of biological novelty by genome evolution is an
important process that gives rise to new organisms and confers
specific characteristics to each phylum. MicroRNAs arose early in
evolution and can be found in distantly related organisms like
plants and animals. However, the processes of biogenesis and target
recognition differ significantly between these kingdoms [13]. When
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analyzing the phylogenetic distribution of animal miRNAs from
early on in evolution, only mir-100 is found to be shared within
eumetazoans (all major animal groups except sponges) [20]. Later
in evolution, three bursts of miRNA innovation occurred. The first
was at the base of the bilaterian lineage, which resulted in 34
miRNAs conserved between deuterostomes (e.g. echinoderms and
chordates) and protostomes (e.g. arthropods and mollusks). The
second miRNA expansion happened at the base of the vertebrate
lineage and the third one occurred in the lineage leading to
eutherian (placental) animals which originated most placental
miRNAs [12]. As a consequence of these events, there is a correla-
tion between the morphological complexity of a given species and
the number of encoded miRNA genes in its genome: according to
miRBase version 17, zebrafish genome comprises 358miRNA genes,
mouse 720 and human 1424 [12].
Recognition of homologous sequences within species is a major
tool for inferring miRNA functionality, and helps to elucidate the
mechanisms involved in their evolution. Since target recognition
depends on a perfect Watson-Crick pairing between the mRNA
30UTR region and the miRNA seed sequence, single nucleotide
changes in either of these sequences may alter the function of a
miRNA and, consequently, miRNA evolution is strictly related to
the evolution of mRNA targets. Frequently, changes in the protein-
coding sequences of genes result in a lethal disruption of protein
function. Thus, changes in the miRNA target sequences are more
desired because they have weaker effects and can contribute to
the fine tuning of gene expression without risking protein func-
tionality [21]. The evolutionary pressure that influences natural
selection, enforcing conservation or favoring divergence in the
sequences of miRNAs:mRNA targets, can be classified into three
groups: positive selection (programmed selection), neutral selec-
tion and negative selection (anti-targets), depending on how
miRNA:mRNA interactions affect the organism [21]. Interestingly,
the majority of miRNA targets are not conserved, suggesting
neutral or negative selection [21]. Further, it has been shown that
mutations in miRNA target sequences occur mostly in the human
lineage [22]. As a consequence of these mechanisms, several
miRNAs are differentially expressed between species; they can be
tissue-restricted and can also vary temporarily within the same
tissue [18].
3. Placenta miRNAs, expression and interspecies differences
With the appearance of the placenta in evolution, new miRNAs
have emerged, which are not expressed, or only marginally so, in
other tissues and organs. To date, more than 500miRNAs have been
reported to be expressed by the human placenta, either in studies
from placental tissue [23,24] or isolated trophoblast cells [14,15].
We have previously reported the expression of 762 miRNAs in
trophoblast cells isolated from first and third trimester placenta,
but only 382miRNAswere notably expressed (Ct< 35) [15]. Several
similarities can be observed when comparing miRNA profiles of
isolated trophoblast cells and whole placenta tissue. For instance,
miR-21, miR-199a, miR-30b, miR-191, miR-24 and miR-30c are
among the highest expressed miRNAs in both samples [15,24],
suggesting trophoblast cells as themain source of placentamiRNAs.
Further, when comparing first and third trimester trophoblast
cells, 31 miRNAs were up-regulated and 14 miRNAs were down-
regulated by more than 100-fold [15]. Remarkably, some of these
miRNAs belong to three highly expressed clusters: C14MC, C19MC
and the miR-371-3 cluster [15]. Changes in the expression of these
miRNAs with the gestational age suggest an involvement in the
regulation of physiological processes. Here, we review aspects of
evolutionary conservation of these clusters among species and of
further human-specific miRNAs expressed in the placenta.
3.1. The chromosome 14 microRNA cluster (C14MC)
Comprising 54 identified members, C14MC at the DLK1-DIO3
genomic region on chromosome 14 represents the largest known
microRNA cluster in humans [25]. Its origin dates back to a pre-
cursor sequence that was amplified by tandem duplication and
which remains structurally unchanged among species [18]. C14MC
is widely conserved in placental mammals but some species di-
vergences have been reported. In mice, the homologous microRNA
cluster is found on chromosome 12 at the DLK1-GTL2 region [26].
However, out of 52 human C14MC miRNAs analyzed on the pre-
cursor level, nine lack an ortholog in mice (hsa-miR-432, -654,
-300, -1185-1, -1185-2, -889, -655, -541 and -656) [27] (Fig. 1).
Similarly, analysis of the mir-379/mir-656 region of C14MC at the
genomic level revealed differences between mouse and human in
regard to gene conservation. For instance, no evidence for an
ortholog in mouse was found for genes of human miR-329-2, -889,
-655, -487a and -656. On the other hand, genes for themurinemiR-
679, -666 and -667were absent in humans [28]. Similar differences
were also observed even between more closely related species, e.g.
the gene for miR-654 can be found in mice but not in rats [28].
Members of the C14MC are among the highest expressed miR-
NAs in primary first trimester trophoblast cells and also in the
immortalized cell line HTR-8/SVneo [15]. Their expression de-
creases towards the third trimester and they were almost not
detectable in JEG-3 cells or its AC-1 mutant-derived hybrids ACH-
3P and AC1-M59 cells [15]. Interestingly, miR-656 that was
down-regulated more than 100-fold in third compared to first
trimester trophoblast cells [15], belongs to the human miRNAs
which do not occur in mice [27,28]. Since dysregulation of this
miRNA and other C14MC members is reported to contribute to
cancer development [29], it will be interesting to analyze their role
in human pregnancy and its pathologies.
3.2. The C19MC and the miR-371-3 cluster
Both these clusters are encoded on chromosome 19 and are
predominantly expressed in placental tissue and in stem cells
[23,30]. C19MC may be one of the most interesting clusters with
regard to placental development during the course of human
evolution, because it only appears in primates [31], while orthologs
of miR-371-3 cluster can be found in other eutherian mammals
including mouse [18].
C19MC consists of 46 miRNA genes which are mostly conserved
among primate species [18]. Nevertheless, analysis of C19MC
miRNA precursors revealed 13 human miRNAs lacking orthologs in
marmoset, and three which are missing in macaque [27] (Fig. 1).
C19MC members are strongly expressed in the human placenta
[23], and are among the highest expressed miRNAs in third
trimester trophoblast cells and in the choriocarcinoma cell lines
JEG-3, ACH-3P and AC1-M59 [14,15]. In contrast to the expression of
C14MC, C19MC members are poorly expressed in first trimester
pregnancy, but their levels increase with gestational age [15,24].
This correlation suggests an association between their expression
and the rapid growth and development of the placenta. However, it
cannot be assumed that only trophoblast cells are responsible for
their expression because new reports have demonstrated expres-
sion also in other placental cells, e.g. mesenchymal stem cells [32].
The miR-371-3 cluster is a small cluster consisting of miR-371,
-372 and -373. Besides the fact that on the precursor level no
orthologs can be found in the mouse [27], this cluster is considered
homologous to the mouse cluster miR-290-295 based on the
conserved seed sequences [33]. We found expression of the miR-
371-3 cluster in primary trophoblast cells and its expression
increased slightly in the third trimester. A large difference in
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expression was observed between choriocarcinoma cell lines and
the HTR-8/SVneo cell line. JEG-3 cells and their hybrids express the
miR-371-3 cluster, while immortalized HTR-8/SVneo do not [15].
These dissimilarities go in line with reported differences in gene
and protein expression between these cell lines [34,35]. Besides the
known differences in their origin (HTR-8SVneo were immortalized
while JEG-3 cells were obtained from choriocarcinoma tissue), the
main reason for absence of C19MC and miR-371-3 in HTR-8SVneo
cells is not yet known. Nonetheless, as C19MC and miR371-3 are
mainly expressed in cells with stemness capacities [30], it may be
argued that freshly isolated cytotrophoblast cells and choriocarci-
noma cell lines contain a fraction of cells with these capacities,
while extravillous trophoblast cells which were the source for
HTR8/SVneo do not. Likewise, the function of these clusters re-
mains unclear although recent reports suggest a role in cell main-
tenance and cell differentiation [15].
3.3. Human-specific microRNAs
The search for orthologs of human mature miRNAs in 11 species
also revealed 10 miRNAs which are human-specific and 12 further
miRNAs with human-specific seed sequences [27] (Fig. 1). Most of
these miRNAs exhibit low expression but miR-941 showed
remarkable abundance in different tissues [27]. In our hands, miR-
941 is expressed in primary trophoblast cells of the first trimester,
but was not detectable in those of third trimester. MiR-941 is
expressed by JEG-3, AC1-M59 and HTR-8/Svneo cells, but not by
ACH-3P cells [15]. The expression of this miRNA in first trimester
trophoblast and in cancer cells goes in line with reports about
reduced expression of miR-941 upon stem cell differentiation and
its potential prominent role in carcinogenesis [27]. Several of the
confirmed targets of miR-941 are involved in insulin-associated
intracellular signaling pathways, which exist also in trophoblast
cells, such as in Wnt signaling, TGF-ß signaling, phosphoinositide-
3-kinase, PPAR-gamma and others [27], To our best knowledge,
thus far, no studies have been done on specific effects of miR-941 in
the placenta.
Further human-specific miRNAs that were detected in tropho-
blast cells and trophoblast cell lines are miR-572 and miR-1302.
While their expression was low in primary first and third
trimester trophoblast cells, it was high in all tested cell lines.
Remarkably, miR-572 is strongly expressed in the choriocarcinoma
cell line JEG-3 [15].
To our knowledge not all known human-specific miRNAs have
been investigated in placental tissue or in isolated placental cells.
Their expression patterns and role in the evolution of the human
placenta and its disorders remain to be investigated.
4. Future of placenta miRNAs as clinical biomarkers
Numerous novel miRNAs have appeared simultaneously with
the development of the placenta in evolution. Some of them have
Fig. 1. Orthologs of the main human placental miRNA clusters in animals. Information on miRNAs belonging to pregnancy-related C14MC, C19MC and miR-371-3 clusters [18] has
been extracted from a recent publication detecting orthologs for all 1733 annotated mature human miRNAs (miRBase version 17) across 11 species by BLAST [27]. Only miRNAs with
no orthologs in a specific species are listed. Human-specific miRNAs correspond to those for which no orthologs in any species have been reported. Illustration by Ospina-Prieto.
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Table 1
Selection of validated targets of potential miRNA biomarkers. PE: Preeclampsia, SGA: Small for gestational age, PTD: Pre-term delivery, GDM: Gestational diabetes mellitus, EP:
Ectopic pregnancy.
MicroRNA Target Cell type Ref
PE/SGA/PTD
miR-210 HSD17B1 Hydroxysteroid (17-beta) dehydrogenase 1 Placenta tissue [43]
ISCU Ironesulfur cluster scaffold homolog Swan 71 cells [39]
miR-517a AREG Amphiregulin Bladder cancer [51]
BCLAF1 BCL2-associated transcription factor 1 Bladder cancer
PE/SGA
miR-21 PTEN Phosphatase and tensin homolog Mz-ChA-1 human cholangiocarcinoma
cell lines
[44]
TPM1 Tropomyosin 1 (alpha) MCF-7 cells
BCL2 B-cell CLL/lymphoma 2 MCF-7 cells




miR-181a BCL-2 B-cell CLL/lymphoma 2 K562/A02 Leukemia cell line [52]
Tcl1 T-cell leukemia/lymphoma 1 Chronic lymphocytic leukemia [44]
miR-136 AEG-1 Astrocyte elevated gene-1 Glioma [46]
Bcl-2 B-cell CLL/lymphoma 2 Glioma
miR-15b CCNE1 Cyclin E1 Glioma [47]
PE/GDM
miR-222 P57 Cyclin-dependent kinase inhibitor Hepatocellular carcinoma, breast, prostate
and pancreatic cancer
[48]
FOXO3 Forkhead box O3 Breast cancer cell lines
TIMP3 TIMP metallopeptidase inhibitor 3 Gastric cancer
MMP1 Matrix metaloproteinase 1 Tongue squamous cell carcinoma
SOD2 Manganese superoxide dismutase Tongue squamous cell carcinoma
cKIT Tyrosine-protein kinase Kit Cord blood cells [44]
miR-29a Insig1 Insulin-induced gene 1 HepG2 [36]
PCK2 Phosphoenolpyruvate Carboxy Kinase 2 HepG2
PE/EP
miR-519d CDKN1A/p21 Cyclin-dependent kinase inhibitor 1A (p21, Cip1) Hepatocellular carcinoma cells [53]
PTEN Phosphatase and tensin homolog
AKT3 V-akt murine thymoma viral oncogene homolog 3
(protein kinase B, gamma)
TIMP2 TIMP metallopeptidase inhibitor 2
PTD
miR-199a* COX-2 Cyclooxygenase-2 Osteoarthritis chondrocytes [54]
miR-338 PTPRT Protein tyrosine phosphatase, receptor type, T Neuroblastoma [55]
miR-449 GMNN Geminin, DNA replication inhibitor Gastrin KO mice [56]
MET Met proto-oncogene (hepatocyte growth factor receptor)
CCNE2 Cyclin E2
SIRT1 Sirtuin 1
miR-483-5p ERK1 Extracellular signal-regulated kinase 1 Glioma [57]
miR-493 RhoC Ras homolog family member C Bladder cancer [58]
FZD4 Frizzled family receptor 4
GDM
miR-132 PTEN Phosphatase and tensin homolog Primary neurons and PC12 cells [49]
FOXO3a Forkhead box O3
P300 E1A binding protein p300
PE
miR-20a VEGFA Vascular endothelial growth factor A Bewo cells [59]
EFNB2 Ephrin-B2
EPHB4 EPH receptor B4
MMP2 Matrix metalloproteinase 2
HIF1A Hypoxia inducible factor 1, alpha subunit
(basic helix-loop-helix transcription factor)
E2F1 E2F transcription factor 1 HeLa [44]
miR-155 CCND1 Cyclin D1 Htr8/svneo [60]
miR-517c Pyk2 Protein tyrosine kinase 2 beta Hepatocellular carcinoma [61]
miR-26b SLC7A11 Solute carrier family seven member eleven Human breast cancer MCF7 cells and
clinical samples
[62]
miR-1 JCN Junctin Cardiomyocytes [63]
miR-223 GZMB Granzyme B Natural killer (NK) cells [64]
STAT3 Signal transducer and activator of transcription 3 Macrophage
E2F1 E2F transcription factor 1 AML blast
FOXO1 Forkhead box O1 Cancer cell lines
miR-26a Bcl-2 B-cell CLL/lymphoma 2 Hepatocellular carcinoma cells [65]
Mcl-1 Myeloid cell leukemia sequence 1 (BCL2-related)
CCND1 Cyclin D1
MMP2 Matrix metalloproteinase 2
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been conserved through all placental mammals; others, as the
above described, are restricted to smaller or larger groups of spe-
cies. A major source of placental miRNAs is villous trophoblast,
which is able to release miRNA containing exosomes into the
maternal circulation suggesting their potential for becoming novel
biomarkers for prediction and detection of pathologies in preg-
nancy [14,24].
Shallow extravillous trophoblast invasion and incomplete
endovascular transformation are frequently associated with preg-
nancy disorders including preeclampsia, gestational diabetes, in-
trauterine growth restriction and low birth weight [19,36,37].
Preeclampsia is one of the major causes of maternal and perinatal
morbidity and mortality worldwide with 5%e8% of all pregnancies
being affected by this condition [38,39]. Besides the well-known
features such as hypertension and proteinuria, preeclampsia is
also associated with impaired implantation, endothelial dysfunc-
tion, and systematic inflammation in themother [38]. Preeclampsia
is often associatedwith intrauterine growth restriction, trophoblast
hypoxia and defective placental development or function [40].
Aiming to unravel the role of miRNAs in the development of these
diseases, several studies have been carried out comparing miRNA
expression in placental tissue or maternal serum of preeclamptic
women with that of normal pregnancies. As an attempt to
consolidate the information regarding miRNAs in these and other
pathologies, we have briefly summarized previously reviewed
studies [18,19] and included recent data [38,39,41]. These studies
have used samples obtained after delivery from patients with
preeclampsia and term-matched normal pregnancies. Only in-
vestigations on ectopic pregnancy (EP) and gestational diabetes
mellitus (GDM) were performed with serum from patients below
20 weeks of gestation. For estimation of functions of these miRNAs,
we have compiled targets involved in the cell cycle, cell prolifera-
tion or cell differentiation (Table 1).
We found 15 reports on miRNAs in preeclampsia but only few
studies on small for gestational age (SGA), preterm delivery (PTD),
EP and GDM (Fig. 2). Interestingly, data differ between studies and
only few miRNAs have been commonly found in at least two in-
vestigations (Fig. 2: underlined miRNAs). This may be due to rela-
tive small study sizes (5-34 patients), intrinsic patient variations,
different definitions of preeclampsia, inclusion criteria and vari-
ability in the methodologies, e.g. in the RNA extraction protocols,
gene array platforms or statistical analyses. Despite that, some
miRNAs are consistently reported dysregulated in different preg-
nancy pathologies and their further study may be worth pursuing.
In the case of preeclampsia, thus far, 110 miRNAs have been
reported to be dysregulated, out of which only 12 are named in at
least two independent studies (Fig. 2). Only miR-210 is dysregu-
lated in three different pathologies, which indicates its importance
in normal placentation. It is up-regulated in preeclampsia and small
for gestational age (reviewed by Ref. [18]), but down-regulated in
preterm delivery (PTD) [37]. The physiological role of miR-210 is
not yet defined, but growing evidence indicates that up-regulation
of miR-210 is associated with altered placental gene expression in
response to hypoxic stimuli [39,42]. MiR-210 is expressed pre-
dominantly by syncytiotrophoblast. Further, a main target is
HSD17B1, a placental steroidogenetic enzyme whose reduction
may predict onset of preeclampsia [43] (Table 1). In the trophoblast
cell line Swan 71, miR-210 inhibits invasiveness by targeting irone
sulfur cluster scaffold homolog (ISCU) [39]. Altogether, alteration of
miR-210 expression may be linked to pregnancy pathologies with
shallow placentation like preeclampsia, intrauterine growth re-
striction and preterm delivery.
Similar to miR-210, miR-21 and miR-16 are dysregulated in
preeclampsia and intrauterine growth restriction (Fig. 2). Both
miRNAs are considered oncomiRs because they are located in
cancer-associated genomic regions, they are able to regulate inva-
sion, and their targets are mainly tumor suppressors [44] (Fig. 2,
and Table 1). MiR-21 is the most highly expressed miRNA in
trophoblast cells [15] and in placental tissue [24], and its expression
is upregulated in JEG-3 cells stimulated with leukemia inhibitory
factor (LIF) [45] indicating its involvement in the control of
trophoblast proliferation and invasion.
To our knowledge, only two studies on miRNAs in preterm de-
livery have been published (reviewed by Ref. [19]). The results show
three miRNAs (miR-181a, -136 and -15b) dysregulated in placenta
tissue from women with PTD as well as in samples of PE patients
[19] (Fig. 2). Their potential targets include BCL-2, a protein that
regulates cell death [44,46] and cyclin E1 which is involved in cell
Fig. 2. Potential miRNA biomarkers in clinical pathologies and their orthologs in animal models. A) Venn diagram. PE: Preeclampsia, SGA: Small for gestational age, PTD: Pre-term
delivery, GDM: Gestational diabetes mellitus, EP: Ectopic pregnancy. MiRNAs underlined were found to be dysregulated in at least two independent studies. Arrows describe up- or
down-regulation when compared to normal pregnancies. Overlapping fields display miRNAs affected by all respective pathologies. If two contrary effects were reported, arrows’
colors are congruent with that of the respective pathology. “n” expresses number of publications reviewed in this manuscript. B) Chromosomal localization, sample origin and lack
of orthologs in animal models. PT: Placental tissue, S: Serum, PL: Plasma, CM: Chorioamniotic membranes. Chi: Chimpanzee, Go: Gorilla, Ora: Orangutan, Mac: Macaque, Mar:
Marmorset, Rat: Rat, Mou: Mouse, Dog: Dog, Cow: Cow, Op: Opossum.
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cycle regulation [47] (Table 1), but themiRNA-target interaction has
not been confirmed in placenta.
In the development of gestational diabetes mellitus (GDM), the
role of miRNAs remains largely unexplored. A recent publication
shows that miR-29a, miR-132 and miR-222 were significantly
down-regulated in GDM patients [36]. MiR-29a targets Insig1 and
PCK2, which are relevant molecules for gluconeogenesis and fatty
acid metabolism. Thus, miR-29 may be a negative regulator of
serum glucose and a novel candidate biomarker for predicting GMD
[36]. The role of miR-222 remains unclear because it depends on
the cellular context: miR-222 can act as an oncomir regulating p57,
FOXO3 and TIMPs, but also can inhibit invasion by reducing MMP-1
and SOD2 [48]. Finally, miR-132 in primary neurons and PC12 cells
controls cell survival by direct regulation of PTEN, FOXO3a and
P300 [49].
Study of ectopic pregnancy revealed four miRNAs dysregulated
when comparedwith spontaneous abortion and viable intrauterine
pregnancy [50] (Fig. 2). Among them, miR-323-3p was significantly
increased in ectopic pregnancy, and its expression predicted these
cases with a sensitivity of 37% and a specificity of 90%. Combined
measurement of hCG, progesterone and miR-323-3p levels was
able to discriminate between ectopic and normal pregnancy with a
sensitivity of 93% and a specificity of 72% indicating a great diag-
nostic potential [50].
Since animal models frequently are employed for the study of
pregnancy pathologies, we decided to investigate the homologous
precursor sequences of the above described miRNAs. Besides
members of the placenta-specific miRNA clusters, some other
miRNAs with potential as biomarkers lack orthologs in models
widely used like mouse (miR-16, -449c, and -483-5p), rat (miR-
182*, -1, -26a-2, -181a-2, -199a*-1, -449c and -483-5p), and even
chimpanzee (miR-483-5p and -132) (Figs. 1 and 2). Lack of ho-
mologous sequences in animals may suggest that those miRNAs
play a role in the development of human-specific pregnancy
pathologies.
5. Conclusions
The above reviewed studies indicate the future usage of miRNAs
as biomarkers for pregnancy disorders. Several of these miRNAs do
not have orthologs in species widely used as experimental models
(Figs. 1 and 2). Therefore, it can be concluded that the use of animal
models inmiRNA researchmay provide results often not relevant for
humans or not predicting their functions in human pregnancy. Due
to the differentmiRNA expressed in non-human species, but also due
to the enormous differences in target sequences, it is hard to esti-
mate the extent of transferability of animal models to humans. Hu-
man ex vivo and in vitro models may more closely display human
physiology and pathology than animals can do.
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Figure 2. Effect of miR-21 silencing and overexpression on cell proliferation 12 






Figure 3. Effect of miR-21 silencing and overexpression on JEG-3 and HTR-19 
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Chapter 5 Discussion 
  
Human implantation is a crucial process for establishment of pregnancy. This 
process requires the coordinated functions of several hormones, cytokines and 
growth factors to be successful. Dysregulation of these factors can result in failure of 
implantation and termination of pregnancy. In the first publication of this thesis, the 
current knowledge of  cytokines present at the implantation site and their influence on 
trophoblast cell functions has been reviewed (Fitzgerald et al. 2011). Among them, 
the IL-6 cytokine family plays an important role in human pregnancy. LIF, a member 
of the IL-6 family, has been most intensively studied in normal and abnormal 
conditions because of its essential function for blastocyst implantation.  
LIF, LIFR and gp130 knockout mice have been intensively investigated. In LIF-
deficient mice, failure of blastocyst implantation is often observed (Stewart et al. 
1992). Interestingly, after infusion of LIF into the uterine lumen of these mice, the 
blastocyst can attach to the uterus resulting in normal pregnancy (Stewart et al. 
1992). Lack of LIFR can result in normal implantation but with development of 
placenta dysfunction (Ware et al. 1995). Likewise, disruption of gp-130 gene causes 
embryonic lethality between day 12.5 and day 18 of gestation (Akira et al. 1995). In 
humans, LIF has been detected in uterine flushings from fertile women during time of 
expected implantation and in women with unexplained infertility LIF concentration is 
lower (Laird et al. 1997). LIF is expressed in endometrium and blastocyst during pre-
implantation, and it is highest expressed in endometrium during implantation (Bhatt et 
al. 1991). In addition, LIF and its receptor are expressed by villous and extravillous 
trophoblast cells throughout pregnancy (Sharkey et al. 1999). OSM is a member of 
the IL-6 cytokine family and plays an important role in placental endocrine functions 
by inducing HCG release (Ogata et al. 2000). OSM concentration is significant higher 
in serum of pregnant women than in non-pregnant women (Ogata et al. 2000). 
Additionally, OSM stimulates trophoblastic cell proliferation and migration through 
STAT3 activation (Ko et al. 2013). In humans, OSM shares the gp130 receptor chain 
with LIF, (Richards 2013). Thus, it may be expected that LIF and OSM exhibit similar 
biological functions in trophoblastic cells. We have recently shown that at low 




concentrations neither LIF nor OSM (10 ng/ml) has an effect on trophoblast cell 
proliferation, whereas, only LIF significantly increases trophoblast cell invasion 
(Chaiwangyen et al. 2014). Higher concentrations of OSM (20 ng/ml) have been 
shown to increase trophoblast cell proliferation, migration and invasion (Ko et al. 
2012, Ko et al. 2013). These findings demonstrate that LIF and OSM are essential for 
blastocyst implantation and placental development potentially by controlling 
trophoblast functions. We have reported that, probably due to sharing their receptors, 
LIF and OSM have the capacity to activate STAT3 and ERK1/2 phosphorylation at 
different intensities (Chaiwangyen et al. 2014). Previously, our group has shown that 
LIF induces trophoblast cell invasion via STAT3 activation, while ERK1/2 activation is 
responsible for trophoblastic cell proliferation (Poehlmann et al. 2005, Prakash et al. 
2011). The process of trophoblast cell invasion into decidual stroma is regulated by 
the activities of MMP-2 and MMP-9 (Pollheimer et al. 2014, Librach et al. 1991, 
Campbell et al. 2003, Shimonovitz et al. 1994). Our study demonstrates that LIF 
mediates trophoblast cell invasion by increasing MMP-2 and MMP-9 secretion 
through STAT3 activation (Chaiwangyen et al. 2014). Altogether, LIF shares 
JAK/STAT signaling with OSM but triggers different biological effects. 
 
It is well documented that miRNAs are expressed in placenta tissues, trophoblast 
cells and maternal blood (Morales-Prieto et al. 2014, Morales-Prieto et al. 2012, Xie 
et al. 2014, Sarker et al. 2014). Therefore, most miRNAs may have the potential of 
serving as biomarkers.  Our previous studies demonstrate changes of miRNA 
expression in trophoblast cells upon LIF stimulation (Morales-Prieto et al. 2011). 
Therefore, based on these findings and existing literature we aimed to investigate 
miRNA expression in different trophoblastic cell lines and primary trophoblast cells. 
Our result is consistent with the finding of Donker et al that placenta abundantly 
expresses miRNAs belonging to the clusters C19MC, C14MC and miR-371-3 
(Morales-Prieto et al. 2012, Donker et al. 2012). C19MC is the largest human miRNA 
gene cluster. It is also highly expressed in other tissues, for instance embryonic stem 
cells and testis (Morales-Prieto et al. 2013, Ouyang et al. 2014). C14MC is 
conserved in mammals including mouse (Morales-Prieto et al. 2013, Ouyang et al. 
2014). The miR-371-3 cluster is conserved in mammals and highly expressed in 
embryonic stem cells (Morales-Prieto et al. 2013). The level of C19MC expression 




increases from first trimester placenta to third trimester placenta, whereas the 
expression of C14MC decreases from first trimester placenta to third trimester 
placenta (Morales-Prieto et al. 2012). Consistently with isolated trophoblast cells, 
C19MC miRNAs are highly expressed in JEG-3 and BeWo choriocarcinoma cells 
(Morales-Prieto et al. 2012, Luo et al. 2009), while HTR-8/SVneo cells (immortalized 
first trimester trophoblast) predominately express C14MC miRNAs (Morales-Prieto et 
al. 2012). These findings may be responsible for differences in proliferation and 
invasive capabilities of these cell lines. These results suggest that C19MC, C14MC 
and miR-371-3 miRNAs have important regulatory roles on trophoblast cell functions 
and placental development throughout pregnancy. Interestingly, our experiments 
reveal that miR-21 is one of the highest expressed miRNA in first trimester 
trophoblast cells (Morales-Prieto et al. 2012).  
 
Individual miRNAs have been analyzed to discover their tissue specificity as well as 
their regulatory functions. So far, a limited number of miRNAs have been investigated 
in regard to their physiological and pathological functions in pregnancy. Recent 
studies demonstrated that dysregulation of more than 50 miRNAs are associated 
with preeclampsia by comparison of miRNAs expression profiles between 
preeclamptic- and normal placentas (Lee et al. 2011, Fu et al. 2013b, Luo et al. 2012, 
Bai et al. 2012, Hu et al. 2009, Zhu et al. 2009, Pineles et al. 2007, Ishibashi et al. 
2012, Zhang et al. 2010, Wang et al. 2012b). Some of these miRNAs have been 
analyzed for their functional roles associated with preeclampsia including shallow 
invasion of trophoblast cells, reduced trophoblast proliferation and deficient maternal 
spiral artery remodeling. For example, miR-210 is up-regulated in preeclamptic 
placentas which display reduced trophoblast cell invasion (Enquobahrie et al. 2011, 
Pineles et al. 2007, Zhu et al. 2009, Zhang et al. 2012). Up-regulated miR-16 is 
associated with severe preeclampsia. Overexpression of miR-16 inhibits trophoblast 
cell migration and formation of tube like structures in HUVEC cells (Wang et al. 
2012c). 
Although miRNAs are produced by placenta and have regulatory functions on 
trophoblast cells (Table 1) it can be argued that not only placenta specific miRNAs 
regulate placental development and functions. It has been previously reported that 
elevated miR-21 expression is most common in all major classes of human cancers, 




and therefore, known as oncomiR (Buscaglia und Li 2011). Moreover, miR-21 has 
been shown to enhance cell growth and to inhibit apoptosis in several cell culture and 
animal models (Li et al. 2012, Lu et al. 2014). MiR-21 is not belonging to placenta 
specific miRNAs but we have demonstrated that miR-21 is one of the highest 
expressed miRNA in first trimester trophoblast cells (Morales-Prieto et al. 2012). The 
function of miR-21 in trophoblastic cells and placental development has been largely 
unknown. In our studies, we demonstrated that the expression of endogenous miR-
21 is higher in HTR-8/SVneo than in JEG-3 choriocarcinoma cells. The expression of 
miR-21 is positively correlated with proliferation, invasion and migration in HTR-
8/SVneo and JEG-3 cells, which seems to be in line with previous reports that down-
regulated miR-21 is associated with IUGR and preeclampsia (Maccani et al. 2011, 
Choi et al. 2013). These results suggest a leading role of miR-21 in regulation of 
trophoblast cell functions. 
 
To understand the role of miRNAs in biological processes, it is essential to 
experimentally assess the functional relevance of predicted miRNA target sites. In 
general, miRNAs inhibit their target mRNA expression. Accordingly, a significantly 
negative correlation between miRNA and respective potential target mRNA confirms 
this interaction. PTEN and PDCD4 are tumor suppressor genes and have been 
validated as targets of miR-21 which are implicated in cell proliferation, migration, 
invasion and apoptosis in several cell types. (Buscaglia und Li 2011, Li et al. 2014a, 
Blanco-Aparicio et al. 2007, Lankat-Buttgereit und Goke 2009). In our results, we 
show that miR-21 targets PDCD4 in JEG-3 cells, whereas it targets PTEN/AKT in 
HTR-8/SVneo cells. Notably, PTEN-/- knockout mice have high embryonic lethality. 
These results indicate that PTEN is essential for early embryonic development (Di 
Cristofano et al. 1998, Suzuki et al. 1998, Freeman et al. 2006). In addition, PTEN 
plays an important role in implantation and is required for trophoblast invasion. 
Deletion of PTEN gene in mice leads to increased fetal mortality, abnormal 
development of the placental labyrinth, and IUGR (Lague et al. 2010). Furthermore, 
miR-21 is highly expressed at the implantation site which is regulated by the active 
blastocyst (Hu et al. 2008). Our current study demonstrates that miR-21 is involved in 
regulation of PTEN expression, probably mainly in first trimester trophoblast. Thus, 
our results highlight the expression of miR-21 and its targets, PTEN in HTR-8/SVneo 




and PDCD4 in JEG-3 cells, which regulate trophoblast cell proliferation, migration, 
invasion and apoptosis during placental development. Thus, cell specific functions of 
miR-21 are likely to differ in different cell types. The target genes and signaling 
pathways of miRNAs that mediate trophoblast cell functions are still marginally 
understood and need further intensive studies both in vitro and ex vivo. 
 
Several studies indicate that hypoxia may have an important impact during early 
placental development (8-10 weeks of gestation) by causing plugs of maternal spiral 
arteries by EVT cells (Figure 11) (Genbacev et al. 1997, Burton et al. 2002, James et 
al. 2006, Patel et al. 2010). Hypoxia inducible factors (HIFs) are transcriptional 
factors that mediate the cellular response to low oxygen levels and are involved in 
placental vascularization, trophoblast invasion and differentiation (Genbacev et al. 
1997, Pringle et al. 2010, Doridot et al. 2013). More interestingly, miR-21 is one of 
hypoxamiRs which can regulate the expression of HIF1α in hypoxic stress 
(Nallamshetty et al. 2013, Kulshreshtha et al. 2007, Gorospe et al. 2011). Moreover, 
HIF1α regulates miR-21 expression by binding to hypoxia response element of miR-
21 (Mace et al. 2013). These results strongly support our hypothesis that miR-21 
regulates trophoblast cell functions during first trimester pregnancy. Prolonged fetal 
hypoxia is associated with IUGR and discovery of hypoxia-induced miRNAs in the 
maternal circulation has indicated its potential for becoming an IUGR biomarker 
(Bamfo und Odibo 2011, Regnault et al. 2007). It has been reported that miR-21 is 
highly expressed in maternal blood of severe FGR when compared to normal 
pregnancy (Whitehead et al. 2013) and  placentas of IUGR and PE (Cindrova-Davies 
et al. 2013). Additionally, hypoxic conditions induce miR-21 expression in villous 



































miRNAs have been detected in extracellular fluids such as serum or plasma (Mitchell 
et al. 2008, Luque et al. 2014). MiRNAs are packed and released from many 
tissue/cell types into extracellular compartments via microparticles (exosomes, 
microvesicles, apoptotic bodies) (Valadi et al. 2007, Zernecke et al. 2009). 
Circulating miRNAs are factors of long distance cell-cell communication and have 
emerged as powerful biomarkers for human diseases (Chen et al. 2012, Turchinovich 
et al. 2013, Creemers et al. 2012, Kosaka et al. 2013). miRNAs of the C19MC cluster 
are secreted into maternal circulation via exosomes which are highly expressed 
throughout gestation (Donker et al. 2012, Richardson 1990). The function of 
extracellular C19MC miRNAs includes the protection of the embryo from viral 
infection (Mouillet et al. 2014, Ouyang et al. 2014, Bullerdiek und Flor 2012). It has 
 
Figure 11. Extravillous trophoblast (EVT) cells block uterine spiral arterioles during first 
trimester pregnancy. A) Spiral artery before pregnancy, which forms a capillary plexus below 
uterine surface. B) At early first trimester pregnancy, endovascular EVT cells plug spiral 
arteries leading to low oxygen tension which is important for placenta development. C) 
Endovascular EVT cells remodel spiral arteries resulting in increased vascular diameter, blood 
flow and oxygen supply. Taken from Patel et al (Patel et al. 2010) 




been demonstrated that up-regulated miR-210 in serum of pregnant women is 
significantly associated with preeclampsia (Anton et al. 2013). Moreover, miR-210 
levels can predict the progression of hypertensive disorders of pregnancy (HDPs) 
several months before the onset of symptoms (Anton et al. 2013). Thus, high levels 
of circulating miR-210 in pregnant women have a potential for becoming biomarker 
for prediction and diagnosis of preeclampsia.  
 
Double stranded miRNAs or miRNA mimics containing the same sequence as the 
mature endogenous miRNA have been used to replace specific miRNAs that are 
down-regulated in diseases. Injection of Let-7 mimic can reduce tumor burden in a 
mouse xenograft model (Trang et al. 2010). Mir-34 is a tumor suppressor miRNA 
which inhibits cell proliferation and increases cell apoptosis. Synthetic miR-34 mimic 
(MRX34) is applied in a phase I clinical trial for liver-based cancers which will be 
completed by the end of first quarter of 2015 (Kelnar et al. 2014, Bouchie 2013). On 
other hand, specific antisense oligonucleotides (antagomiRs) have been developed 
for reducing miRNA levels which are up-regulated in pathological conditions. For 
example, Miravirsen which is antogomiR-122 reduces viral RNA with no evidence of 
resistance in hepatitis C (Janssen et al. 2013). Currently, Miravirsen is evaluated in a 
phase 2 clinical trial for treatment of Hepatitis C virus (HCV) infection (Gebert et al. 
2014). Side effects, drug target delivery, and drug stability need to be further 
improved. The next challenge will be the development of strategies in order to 
increase or decrease specific miRNA levels in placenta aiming to prevent the 
progression of pregnancy related diseases.  
 




Chapter 6 Conclusion 
 
Cytokines and miRNAs play an important role during implantation and successful 
pregnancy. Our findings suggest that LIF regulates trophoblast cell invasion 
through MMP-2 and MMP-9 activation. Low concentrations of OSM have no effects 
on biological activity of trophoblast cells but its intracellular signals have some 
similarities with those induced by LIF, potentially activated through the gp130 
receptor subunits. OSM has been detected at higher concentrations in serum of 
preeclamptic women than in normal pregnant women but further studies are 
required to confirm the relationship between OSM and preeclampsia. The role of 
OSM and LIF in cell proliferation and invasion seems to be cell type dependent. 
There are several trophoblast cell line models that were generated from different 
sources such as normal placenta, choriocarcinoma tissues and embryonic 
carcinomas for determination of molecular mechanism of trophoblast cell functions 
such as proliferation, invasion and apoptosis (Ji et al. 2013). Therefore translation 
of observed OSM and LIF effects to primary cells should be carefully evaluated.  
Overall, the human placenta expresses miRNAs, which play important roles during 
placental development:  1) different patterns of miRNAs are expressed during 
different gestational stages 2) miRNAs are involved in several trophoblast cell 
functions including proliferation, migration, invasion, apoptosis and angiogenesis 3) 
altered miRNAs expression is associated with pregnancy related disorders, such as 
preeclampsia (Fu et al. 2013a). miR-21 regulates trophoblast cell functions and may 
potentially serve as biomarker for pregnancy complications. Circulating miRNAs may 
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